WO2015178508A1 - Nrf2-based cancer treatment and detection methods and uses - Google Patents
Nrf2-based cancer treatment and detection methods and uses Download PDFInfo
- Publication number
- WO2015178508A1 WO2015178508A1 PCT/JP2015/065702 JP2015065702W WO2015178508A1 WO 2015178508 A1 WO2015178508 A1 WO 2015178508A1 JP 2015065702 W JP2015065702 W JP 2015065702W WO 2015178508 A1 WO2015178508 A1 WO 2015178508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nrf2
- target gene
- cancer
- subject
- expression
- Prior art date
Links
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title claims abstract description 323
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 117
- 201000011510 cancer Diseases 0.000 title claims abstract description 113
- 238000011282 treatment Methods 0.000 title claims description 38
- 238000001514 detection method Methods 0.000 title claims description 21
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title description 93
- 101710114687 Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims abstract description 236
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 187
- DEZJGRPRBZSAKI-KMGSDFBDSA-N 565434-85-7 Chemical compound C([C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C(=C(F)C(F)=C(F)C=1F)F)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 DEZJGRPRBZSAKI-KMGSDFBDSA-N 0.000 claims abstract description 167
- 108010089388 Cdc25C phosphatase (211-221) Proteins 0.000 claims abstract description 165
- 230000014509 gene expression Effects 0.000 claims abstract description 146
- 238000000034 method Methods 0.000 claims abstract description 76
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 claims description 74
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 claims description 69
- 230000000694 effects Effects 0.000 claims description 53
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 230000035772 mutation Effects 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 235000018102 proteins Nutrition 0.000 claims description 42
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 230000006870 function Effects 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 230000007423 decrease Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 20
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 19
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 19
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 17
- 238000001262 western blot Methods 0.000 claims description 15
- 102000005602 Aldo-Keto Reductases Human genes 0.000 claims description 12
- 108010084469 Aldo-Keto Reductases Proteins 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 102000000584 Calmodulin Human genes 0.000 claims description 8
- 108010041952 Calmodulin Proteins 0.000 claims description 8
- 229960003180 glutathione Drugs 0.000 claims description 8
- 101710088194 Dehydrogenase Proteins 0.000 claims description 7
- 101710112780 Gene 1 protein Proteins 0.000 claims description 7
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 108010063907 Glutathione Reductase Proteins 0.000 claims description 7
- 239000003607 modifier Substances 0.000 claims description 7
- 159000000021 acetate salts Chemical class 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229940121871 G2 checkpoint inhibitor Drugs 0.000 claims description 4
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 108010086596 glutathione peroxidase GPX1 Proteins 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 101100337673 Caenorhabditis elegans gpx-1 gene Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 238000012207 quantitative assay Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 claims 3
- 101100059607 Caenorhabditis elegans cec-3 gene Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 89
- 239000000816 peptidomimetic Substances 0.000 abstract description 54
- 210000004027 cell Anatomy 0.000 description 158
- 235000001014 amino acid Nutrition 0.000 description 69
- 229940024606 amino acid Drugs 0.000 description 67
- 150000001413 amino acids Chemical class 0.000 description 66
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 48
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 230000035945 sensitivity Effects 0.000 description 31
- -1 Ras Proteins 0.000 description 30
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 28
- 230000022131 cell cycle Effects 0.000 description 20
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 14
- 229960005559 sulforaphane Drugs 0.000 description 14
- 235000015487 sulforaphane Nutrition 0.000 description 14
- 102000053602 DNA Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 12
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000003197 gene knockdown Methods 0.000 description 11
- 239000004055 small Interfering RNA Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 7
- 238000010208 microarray analysis Methods 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 6
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000006178 malignant mesothelioma Diseases 0.000 description 6
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 5
- 101150005096 AKR1 gene Proteins 0.000 description 5
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 101150012716 CDK1 gene Proteins 0.000 description 5
- 101150006084 CHKB gene Proteins 0.000 description 5
- 102000002427 Cyclin B Human genes 0.000 description 5
- 108010068150 Cyclin B Proteins 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 101100215778 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-1 gene Proteins 0.000 description 5
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 101150113466 cul-3 gene Proteins 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- HASUJDLTAYUWCO-UHFFFAOYSA-N 2-aminoundecanoic acid Chemical compound CCCCCCCCCC(N)C(O)=O HASUJDLTAYUWCO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 3
- 102100029727 Enteropeptidase Human genes 0.000 description 3
- 230000037060 G2 phase arrest Effects 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000021601 lentivirus infection Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- XAUQWYHSQICPAZ-UHFFFAOYSA-N 10-amino-decanoic acid Chemical compound NCCCCCCCCCC(O)=O XAUQWYHSQICPAZ-UHFFFAOYSA-N 0.000 description 2
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- 101710112812 14-3-3 protein Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 2
- VWPQCOZMXULHDM-UHFFFAOYSA-N 9-aminononanoic acid Chemical compound NCCCCCCCCC(O)=O VWPQCOZMXULHDM-UHFFFAOYSA-N 0.000 description 2
- 102100026446 Aldo-keto reductase family 1 member C1 Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 102100031441 Cell cycle checkpoint protein RAD17 Human genes 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000718028 Homo sapiens Aldo-keto reductase family 1 member C1 Proteins 0.000 description 2
- 101001130422 Homo sapiens Cell cycle checkpoint protein RAD17 Proteins 0.000 description 2
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000235343 Saccharomycetales Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001243 acetic acids Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940125648 antineoplastic drug candidate Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000001939 glutaminyl group Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-MRVPVSSYSA-N (2r)-2-amino-3-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-MRVPVSSYSA-N 0.000 description 1
- HKUAWRVNDCVEHT-NSHDSACASA-N (2s)-2-(pyren-4-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC3=CC=CC4=CC=C1C2=C34 HKUAWRVNDCVEHT-NSHDSACASA-N 0.000 description 1
- CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
- 108010019099 Aldo-Keto Reductase Family 1 member B10 Proteins 0.000 description 1
- 102100026451 Aldo-keto reductase family 1 member B10 Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- SRUWWOSWHXIIIA-UKPGNTDSSA-N Cyanoginosin Chemical compound N1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](C)[C@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@H](C(O)=O)N(C)C(=O)[C@@H](C)[C@@H]1\C=C\C(\C)=C\[C@H](C)[C@@H](O)CC1=CC=CC=C1 SRUWWOSWHXIIIA-UKPGNTDSSA-N 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 108010050332 IQ motif containing GTPase activating protein 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 101150069805 MAFG gene Proteins 0.000 description 1
- 108010033714 Maf Transcription Factors Proteins 0.000 description 1
- 102000007307 Maf Transcription Factors Human genes 0.000 description 1
- 102000001947 MafK Transcription Factor Human genes 0.000 description 1
- 108010040548 MafK Transcription Factor Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 244000146510 Pereskia bleo Species 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102100034419 Ras GTPase-activating-like protein IQGAP1 Human genes 0.000 description 1
- QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100021255 Small acidic protein Human genes 0.000 description 1
- 101710174775 Small acidic protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001295 alanines Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000001942 asparaginyl group Chemical group 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000015246 common arrowhead Nutrition 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- LRCTTYSATZVTRI-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(4+);tetradecanoate Chemical compound [Pt+4].NC1CCCCC1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LRCTTYSATZVTRI-UHFFFAOYSA-L 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- TZMFJUDUGYTVRY-UHFFFAOYSA-N ethyl methyl diketone Natural products CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 108010067094 microcystin Proteins 0.000 description 1
- 229950004962 miriplatin Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229950005566 picoplatin Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229960005567 rebeccamycin Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the cell cycle comprises S phase (DNA replication), M phase (mitosis), and two gap phases (Gl and G2 phases) between S and M phases.
- Checkpoints in the cell cycle ensure accurate progression, such as monitoring the state of DNA integrity, DNA replication, cell size, and the surrounding environment (Mailer, J. L. Curr. Opin. Cell Biol., 3:26 (1991)). It is especially important for multi-cellular organisms to maintain integrity of genome, and there are multiple checkpoints that monitor the state of genome. Among them are Gl and G2 checkpoints existing before DNA replication and mitosis, respectively. It is also important to correct DNA damage before entering S phase, because once damaged DNA is replicated it often gives rise to mutations (Hartwell, L. Cell, 71 : 543 (1992)). Progression through G l and G2 checkpoints without repairing extensive DNA damage induces apoptosis and/or catastrophe.
- Gl checkpoint-related proteins such as p53, Rb, MDM-2, pl6INK4 and pl9ARF (Levine, A. J. Cell, 88:323 (1997)).
- mutations can cause over-expression and/or over activation of oncogene products, e.g., Ras, MDM-2 and cyclin D, which reduce the stringency of Gl checkpoint.
- oncogene products e.g., Ras, MDM-2 and cyclin D
- excessive growth factor signaling can be caused by the over expression of growth factors and can reduce the stringency of Gl checkpoint.
- continuous activation of growth factor receptors or downstream signal- transducing molecules can cause cell transformation by overriding the Gl checkpoint.
- G2 checkpoint Abrogated G l checkpoint contributes to higher mutation rates and the many mutations observed in cancer cells. As a result, most cancer cells depend on G2 checkpoint for survival against excessive DNA damage (O'Connor and Fan, Prog. Cell Cycle Res., 2: 165 (1996)).
- Cdc2/Cyclin B kinase is kept inactive because of inhibitory phosphorylation of threonine- 14 and tyrosine-15 residues on Cdc2 kinase or the protein level of Cyclin B is reduced.
- the dual phosphatase Cdc25 removes these inhibitory phosphates and thereby activates Cdc2/Cyclin B kinase.
- the activation of Cdc2/Cyclin B is equivalent to the onset of M phase.
- Chkl kinase In fission yeast, the protein kinase Chkl is required for the cell cycle arrest in response to damaged DNA. Chkl kinase acts downstream of several rad gene products and is modified by the phosphorylation upon DNA damage.
- the kinases Rad53 of budding yeast and Cdsl of fission yeast are known to conduct signals from unreplicated DNA. It appears that there is some redundancy between Chkl and Cdsl because elimination of both Chkl and Cds l culminated in disruption of the G2 arrest induced by damaged DNA.
- Chk2/HuCdsl a human homologue of the budding yeast Rad53 and fission yeast Cdsl, phosphorylate Cdc25C at serine-216, a critical regulatory site, in response to DNA damage.
- This phosphorylation creates a binding site for small acidic proteins 14-3-3s, human homologues of Rad24 and Rad25 of fission yeast.
- the regulatory role of this phosphorylation was clearly indicated by the fact that substitution of serine-216 to alanine on Cdc25C disrupted cell cycle G2 arrest in human cells. However, the mechanism of G2 checkpoint is not fully understood.
- a method comprises a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene; and c) treating the subject having the cancer with PI, P2, P3, P4, P5, P6 (SEQ ID NO: l) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2) (e.g., CBP501) if expression of the NRF2, P3, P4, P5, P6 (SEQ ID NO: l) or P6, P5, P4, P3, P2,
- a method comprises a) screening for a normal or a functional KEAP 1, or a mutation that reduces or decreases activity, function or expression of KEAP 1 in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the presence of a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and b) treating the subject having the cancer with PI , P2, P3, P4, P5, P6 (SEQ ID NO: 1) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2) (e.g., CBP501) if the subject has a normal or a functional KEAP 1 or does not have a mutation that reduces or decreases activity, function or expression of KEAP 1.
- a method comprises a) identifying and/or selecting a subject with a cancer in which NRF2 expression or NRF2 target gene expression in the subject is less than a baseline or reference amount of NRF2 or NRF2 target gene, or where the subject has a normal or a functional KEAP 1 or lacks a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) treating the cancer in the subject with a peptide or peptidomimetic set forth herein (e.g., CBP501 ) as if the NRF2 or the NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene, or if the subject has a normal or a functional KEAP 1 or does not have a mutation that reduces or decreases activity, function or expression of KEAP 1.
- a peptide or peptidomimetic set forth herein e.g., CBP501
- a method comprises, a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene and c) selecting the subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
- NRF2 nuclear factor erythroid-2 related factor 2
- a method includes a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) selecting the subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if normal or a functional KEAP 1 is present or a mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or not present.
- a peptide or peptidomimetic as set forth herein (e.g., CBP501)
- a method in another embodiment, includes a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or NRF2 target gene in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 in order to determine if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene and c) identifying the subject as a candidate for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
- NRF2 nuclear factor erythroid-2 related factor 2
- certain aspects can sometimes comprise, a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) identifying the subject as a candidate for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the normal or a functional KEAP 1 is present, or a mutation mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or not present.
- a method includes a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or NRF2 target gene of cells of a cancer, and determining the amount of NRF2 or NRF2 target gene expressed, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a predetermined value for NRF2 or NRF2 target gene in order to determine if the amount of NRF2 or NRF2 target gene is less or greater than the predetermined value for NRF2 or NRF2 target gene and c) characterizing the cancer as more responsive or less responsive to treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene expression is less than or greater than the predetermined value for NRF2 or NRF2 target gene.
- NRF2 nuclear factor erythroid-2 related factor 2
- a method in another embodiment, includes a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and/or b) characterizing the cancer as more responsive or less responsive to treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the normal or a functional KEAP 1 is present or absent, or a mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or present.
- a peptide or peptidomimetic as set forth herein (e.g., CBP501)
- a NRF2 target gene is any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase familylCl (AKR1C1), Aldo-keto reductase familylC3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1B 10, ⁇ -glutamyl cysteine synthetase modifier subunit (yGCSm) and/or Glutathione peroxidasel (GPX1).
- GSR Glutathione reductase
- G6PD Glucose-6-phosphate dehydrogenase
- ABCC2 ATP-binding cassette sub-familyC member2
- ACR1C1C1 Aldo-keto reductase familylCl
- a baseline or reference level or predetermined value is determined by expression in cancer cells responsive to a peptide or peptidomimetic as set forth herein (e.g., CBP501) treatment compared to cancer cells less-responsive to a peptide or peptidomimetic (e.g., CBP501) as set forth herein treatment.
- a sample comprises a biological sample.
- a sample can comprise a cell, tissue or organ (e.g., lung) biopsy, or a blood or serum sample.
- a subject is a mammal.
- the mammal can be a human.
- a subject is a human.
- expression is measured by a quantitative assay.
- expression is measured with, or detected by contact with an analyte that detects an NRF2 protein or a protein encoded by an NRF2 target gene, or detects KEAP 1 protein or target gene, or a mutation that reduces or decreases activity, function or expression of KEAP 1.
- expression is measured or detected by contact with an analyte that detects an NRF2 transcript, or the transcript of an NRF2 target gene, or by sequencing a nucleic acid that comprises KEAP 1 , or a mutation that reduces or decreases activity, function or expression of KEAP 1 .
- expression is measured or detection is by an immunoassay.
- expression is measured or detection is by an antibody immunoassay. In some embodiments, expression is measured or detection is by a Western blot, ELISA, Northern blot, immunohistochemistry or immunocyotchemistry. In certain embodiments expression is measured or detection is by determining cDNA of NRF2 or cDNA of NRF2 target gene. In some aspects, expression is measured or detection is by reverse transcription of NRF2 RNA or NRF2 target gene RNA and polymerase chain reaction (RT-PCR) of NRF2 cDNA or NRF2 target gene cDNA, or reverse transcription of KEAP 1 RNA or KEAP 1 gene and polymerase chain reaction (RT-PCR) of KEAP 1 cDNA.
- RT-PCR reverse transcription of NRF2 RNA or NRF2 target gene RNA and polymerase chain reaction
- a peptide or peptidomimetic comprises a salt or a pro-drug thereof, or a salt of a pro-drug thereof.
- a salt comprises a sodium, calcium, magnesium, nitrate, potassium, phosphate, sulfonate, fumarate, citrate, carbonate, ascorbate, succinate, trifluoroacetate or acetate salt.
- a method described herein comprises administering a G2 checkpoint inhibitor agent (e.g., a peptide or peptidomimetic such as CBP501). In some embodiments, a method described herein comprises administering a calmodulin binding agent. In some embodiments, a method described herein includes administering a nucleic acid damaging agent to the subject (e.g., a molecule that binds to or intercalates in DNA).
- a G2 checkpoint inhibitor agent e.g., a peptide or peptidomimetic such as CBP501.
- a method described herein comprises administering a calmodulin binding agent.
- a method described herein includes administering a nucleic acid damaging agent to the subject (e.g., a molecule that binds to or intercalates in DNA).
- a method described herein comprises administering a peptide or peptidomimetic (e.g., CBP501), a G2 checkpoint inhibitor agent, a calmodulin binding agent or a nucleic acid damaging agent to the subject 1, 2, 3, 4, 5, or more times, alone, or in any combination.
- a peptide or peptidomimetic e.g., CBP501
- G2 checkpoint inhibitor agent e.g., CBP501
- calmodulin binding agent e.g., calmodulin binding agent
- a cancer comprises a lung cancer (NSCLC).
- NSCLC lung cancer
- a population of cancer cells wherein the cells are fixed or immobilized on a substrate and the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or KEAP 1 protein or gene.
- a population of cancer cells obtained from a subject are fixed or immobilized on a substrate and the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or KEAP 1 protein or gene.
- the reagent that detects an NRF2 protein or a protein encoded by an NRF2 target gene or KEAP 1 protein comprises an antibody.
- a population of cancer cells wherein the cells are fixed or immobilized on a substrate and the cells have bound thereto a reagent that selectively binds to NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript.
- a population of cancer cells obtained from a subject are fixed or immobilized on a substrate and the cells have bound thereto a reagent that selectively binds to an NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript.
- the reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene comprises an oligonucleotide or primer.
- NRF2 target genes include any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase family 1C1 (AKRIC I ), Aldo-keto reductase family 1C3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl ), AKR1B10, ⁇ -glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX1 ).
- GSR Glutathione reductase
- G6PD Glucose-6-phosphate dehydrogenase
- ABCC2 ATP-binding cassette sub-familyC member2
- AKRIC I Aldo-keto reductase family 1C1
- ARR1C3 Al
- compositions comprising nucleic acid isolated, purified or extracted from a population of cancer cells, where the nucleic acid comprises NRF2 gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or a transcript thereof, or binds to KEAP 1 gene or a transcript thereof.
- compositions include nucleic acid isolated, purified or extracted from a population of cancer cells, wherein the nucleic acid comprises an NRF2 target gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or transcript thereof, or binds to KEAP 1 gene or a transcript thereof.
- a reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene comprises an oligonucleotide or primer.
- compositions comprising protein isolated, purified or extracted from a population of cancer cells, where the protein comprises N F2 protein bound to a reagent that selectively detects NRF2 protein, or KEAP 1 protein bound to a reagent that selectively detects KEAP 1 protein.
- compositions include protein isolated, purified or extracted from a population of cancer cells, wherein the protein comprises a protein encoded by an NRF2 target gene bound to a reagent that selectively detects the protein encoded by an NRF2 target gene.
- a reagent that selectively detects NRF2 protein, or protein encoded by an NRF2 target gene, or KEAP 1 protein comprises an antibody.
- NRF2 target genes include any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase family 1C1 (AKR1C1 ), Aldo-keto reductase familylC3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1 B 10, ⁇ -glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX 1).
- GSR Glutathione reductase
- G6PD Glucose-6-phosphate dehydrogenase
- ABCC2 ATP-binding cassette sub-familyC member2
- ALR1C1 Aldo-keto reductase family 1C1
- ARR1C3 Al
- FIGS. 1A-1H show CBP501 sensitivity is characterized in both HI 703 and H1437 NSCLC cell lines by l h co-treatment with CDDP.
- FIGs. 1A-D HI 703.
- FIGs. 1E-H H1437.
- Chi-square tests were performed to compare the change in the cell cycle distribution between CBP501 (SEQ ID NO:80) minus and plus at each CDDP dose point.
- An asterisk indicates statistical significance (pO.001 ).
- N.S. not significant (p>0.05). Error bars indicate the standard deviation from duplicate flowcytometry analyses.
- FIGS. 2A-2D show microarray gene expression analyses indicating an increase in Nrf2 -dependent gene expression in CBP501 insensitive cell lines.
- FIG. 2A Heat-map display of the expression of isolated genes as determined by microarray analysis. Left panel comprises the CBP501 insensitive cell lines. Right panel comprises the CBP501 sensitive cell lines. Green indicates a low level of expression. Red indicates a high level of expression. Black indicates intermediate levels of expression (a value approx. 5000). Experiments were performed in triplicate.
- FIG. 2B Western blot analysis for Nrf2 signaling components in NSCLCs.
- FIG. 2D Western blot analysis for a series of genes initially identified by microarray analysis.
- FIGS 3A-3C show a high degree of Nrf2 nuclear localization correlates with high levels of Nrf2 expression.
- Fig. 3A Immunocytochemistry for Nrf2 in NSCLCs. Left panels show Nrf2 in green. Middle panels show Hoechst dye in red. Right panels show the merged images. Scale bar indicates ⁇ .
- FIG. 3B Nrf2 intensities in whole cells.
- FIG. 3C Nrf2 intensities in nuclei. Error bars signify standard deviations of Nrf2 intensity as determined from the five different images.
- FIG. 4A-D show Nrf2 activating agent Sulforaphane (SFN) cancels the effect of CBP501 ; knock-down of Nrf2 attenuates SFN's effect.
- FIG. 4A Western blot analysis for a series of Nrf2 target proteins in NSCLCs.
- FIG. 4B Confirmation of the efficiency of knockdown by Nrf2 shRNA lentivirus transfection. Upper bands indicated by black arrow head are Nrf2 protein levels. Middle and lower bands indicate internal controls of IQGAP1 and ATM respectively.
- FIGS 5A-C show knock-down of Nrf2 in the CBP501 -insensitive cell line H1437, increases CBP501 sensitivity.
- FIG. 5A Confirmation of knock-down efficiency by Nrf2 shRNA lentivirus infection. Upper bands indicate Nrf2 protein level. Middle three bands are the Nrf2 target molecules AKR1C3, G6PD and GSR respectively. Lower two bands indicate internal controls of IQGAPl and MLC2 alpha respectively.
- FIG. 6A Heat-map display of isolated gene expression levels, as determined by microarray analysis, in a total of twenty-eight NSCLC cell lines. Left panel comprises the CBP501 insensitive cell lines. Right panel comprises the CBP501 sensitive cell lines. Green indicates a value indicating a low level of expression. Red indicates a high level of expression. Black indicates intermediate levels of expression (numerical value approx. 5000). Experiments performed in triplicate. Percentage of correlation between CBP501 sensitivity and isolated gene expression values are indicated at the right side of the heat-map panel. (Fig. 6A) Heat-map display of isolated gene expression levels, as determined by microarray analysis, in a total of twenty-eight NSCLC cell lines. Left panel comprises the CBP501 insensitive cell lines. Right panel comprises the CBP501 sensitive cell lines. Green indicates a value indicating a low level of expression. Red indicates a high level of expression. Black indicates intermediate levels of expression (numerical value approx. 5000). Experiments performed in triplicate. Percentage of correlation between C
- FIG. 6B Western blot analysis for a series of Nrf2 target proteins in NSCLC cell lines extended beyond the original set (Table 2).
- FIG. 6D Immunocytochemistry for AKR1C3 in NSCLCs. Upper panels show APCR1C3 in green. Middle panels show Hoechst dye in red. Lower panels show the merged image. Scale bar indicates ⁇ .
- Figure 7 shows comparative analysis of individual gene expression as in CBP501 insensitive cell lines or the CBP501 sensitive cell lines from Figure 2. Black bars indicate the average values of expression in CBP501 insensitive cell lines. Red bars indicate the average values of expression in CBP501 sensitive cell lines.
- peptides and peptidomimetics employed in connection with the methods disclosed herein.
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO: l) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2).
- PI is Cha, Nal (2), (Phe-2,3,4,5,6-F), , (Phe-3,4,5F), (Phe-4CF 3 ), an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain;
- P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF 3 ), Bpa, Phe4N02, an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine,
- a peptide or peptidomimetic sequence includes the following structure: PI , P2, P3, P4, P5, P6 (SEQ ID NO:3); P6, P5, P4, P3, P2, PI (SEQ ID NO:4); PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:5); PI, P2, P3, P4, P5, P6, P12, Pl l, P10, P9, P8, P7 (SEQ ID NO:6); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:7); P6, P5, P4, P3, P2, PI, P12, Pl l, P10, P9, P8, P7 (SEQ ID NO:8); P7, P8, P9, PI O, Pl l, P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:3); P6, P
- PI is Cha, Nal(2), (Phe- 2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, an amino acid that occupies a similar side chain space (e.g. d- or 1-Tyr, d- or 1-Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain;
- P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe- 3,4,5F), (Phe-4CF3), or an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, PIO, PI 1, P12 (SEQ ID NO:17); P12, PI 1, P10, P9, P8, P7, P6, P5, P4, P3, P2, P1(SEQ ID NO: 18); P12, Pl l, P10, P6, P9, P4, P7, P2, P1(SEQ ID NO: 19); or PI , P2, P7, P4, P9, P6, P10, PI 1, P12 (SEQ ID NO:20).
- PI is Cha, Nal(2), (Phe-
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO:21) or P6, P5, P4, P3, P2, PI (SEQ ID NO:22).
- PI is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe;
- P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe;
- P3 is Ser, Arg, Cys, Pro, or Asn;
- P4 is ⁇ ;
- P5 is Ser, Arg, or Asn; or P3, P4, P5 is a single aminoundecanoic acid or a single 8-aminocaprylic acid; and
- P6 is Bpa, Phe4N02, (Ser-Tyr), or (Ser-Phe).
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:23); PI, P2, P3, P4, P5, P6, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:24); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:25); P6, P5, P4, P3, P2, PI, P12, PI 1, PIO, P9, P8, P7 (SEQ ID NO:26); P7, P8, P9, P10, Pl l , P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:27); P7, P8, P9, PI 0, PI 1, P12, P6, P5, P4, P3, P2, PI (SEQ ID NO:28); P12
- PI is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF 3 ), Bpa, Phe4N0 2 , Tyr, or Phe;
- P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe;
- P3 is Ser, Arg, Cys, Pro, or Asn;
- P4 is Trp;
- P5 is Ser.
- P3, P4, P5 is a single aminoundecanoic acid or a single 8-aminocaprylic acid
- P6 is Bpa, Phe4N0 2 , (d-Ser-d-Tyr), or (d-Ser-d-Phe)
- at least three of P7, P8, P9, PIO, PI 1, P12 are Arg or Lys with the rest being any amino acid or absent.
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:35); P12, Pl l, P10, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:36); P12, PI 1, P10, P6, P9, P4, P7, P2, PI (SEQ ID NO:37); or PI, P2, P7, P4, P9, P6, P10, PI 1 , P12 (SEQ ID NO:38).
- PI is Cha, or Nal(2); P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF 3 ); P3 is Ser; P4 is Trp; P5 is Ser or Asn; P6 is Bpa, Phe4N0 2 , (Ser-Tyr), or (Ser-Phe); and at least three of P7, P8, P9, P10, PI 1, PI 2 are Arg with the rest being any amino acid or absent.
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO:39) or P6, P5, P4, P3, P2, PI (SEQ ID NO.40).
- PI is Cha, or Nal(2);
- P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F) or (Phe-4CF 3 );
- P3 is Ser;
- P4 is ⁇ ;
- P5 is Ser; and P6 is Bpa, or (Ser-Tyr).
- a peptide or peptidomimetic sequence comprising the following structure:Pl, P2, P3, P4, P5, P6 (SEQ ID NO:41); P6, P5, P4, P3, P2, PI (SEQ ID NO:42); PI, P2, P3, P4, P5, P6, P7, P8, P9, PIO, PI 1, P12 (SEQ ID NO:43); PI, P2, P3, P4, P5, P6, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:44); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:45); P6, P5, P4, P3, P2, PI, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:46); P7, P8, P9, PI O, PI 1, P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:41); P6, P5, P4, P
- PI is Cha, or Nal(2); P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F) or (Phe-4CF 3 ); P3 is any amino acid (e.g., Ser, or Pro); P4 is d- or 1-Trp; P5 is any amino acid (e.g., Ser, or Pro); P6 is Bpa or (Ser-Tyr); P7 is Arg; P8 is Arg; P9 is Arg; PIO is Gin or Arg; PI 1 is Arg; and PI 2 is d- or 1-Arg.
- a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:55); P12, PI 1, PIO, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:56); P12, PI 1, PIO, P6, P9, P4, P7, P2, PI (SEQ ID NO:57); or PI, P2, P7, P4, P9, P6, PIO, PI 1, P12 (SEQ ID NO:58).
- PI is Cha or Nal(2); P2 is (Phe-2,3,4,5,6-F); P3 is Ser; P4 is Trp; P5 is Ser; P6 is Bpa or (Ser-Tyr); P7 is Arg; P8 is Arg; P9 is Arg; PIO is Gin or Arg; PI 1 is Arg; and PI 2 is Arg.
- a peptide or peptidomimetic sequence includes the following structure: (d-Bpa) (d-Ser)(d-Trp)(d-Ser) (d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg) (d-Arg) (d-Arg) (d- Gln)(d-Arg) (d-Arg) (CBP501; SEQ ID NO:80); (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Gln)(d-Arg) (d-Arg) (d-Bpa)(d-Ser)(d-Trp)(d-Ser) (d-Phe-2,3,4,5,6-F) (d-Cha) (SEQ ID NO:100); (d-Bpa) (d-Ser)(d- ⁇ ) ⁇ -86 ⁇ ) (d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg) (d-Arg) (
- physiologically acceptable salts of CBP501 for example, a salt of an inorganic base, a salt of an organic base, a salt of an inorganic acid, a salt of an organic acid, a salt of a basic or acidic amino acid and the like.
- Such salts can be produced by a method known methods (e.g., acetate salt can be produced by a step of liquid chromatography using acetate-containing solvent).
- salts with inorganic base include alkali metal salt such as sodium salt, potassium salt and the like, alkaline earth metal salt such as calcium salt, magnesium salt and the like, and aluminum salt, ammonium salt and the like.
- salts with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine,
- salts with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- salts with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
- salts with basic amino acid include salts with arginine, lysine, ornithine and the like.
- salts with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
- salts of an organic acid such as acetic acid and the like.
- the number of acetic acid attached to a peptide or peptidomimetic as set forth herein can vary, including, for example 4 or 5 acetic acids per a peptide or peptidomimetic as set forth herein (e.g., CBP501).
- a mixture of a peptide or peptidomimetic (e.g., CBP501) acetate salts having different number of acetic acids attached thereto for example, mixture of 4 acetate and 5 acetate etc.
- an acetate salt of a peptide compound CBP501 (d-Bpa)(d-Ser)(d-T )(d-Ser)(d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg)(d-Arg)(d-Arg)(d-Gln)(d-Arg)(d- Arg) (SEQ ID NO:80).
- a method of producing an acetate salt of a peptide compound shown by SEQ ID No:80 may comprise a step of performing liquid chromatography using an acetate- containing solvent.
- peptides and peptidomimetic sequences include one or more 1-type or d-type residues; a d-residue substituted with a 1 -residue; or a 1 -residue substituted with a d- residue.
- Peptides and peptidomimetic sequences include one or more of the following activities: inhibits proliferation of a cell; abrogates cell cycle G2 checkpoint of a cell; stimulates apoptosis of a cell; stimulates catastrophe of a cell.
- Peptides and peptidomimetic sequences include a sequence having a length from about 6 to about 12, 10 to about 20, 18 to about 25, 25 to about 100, 25 to about 200, or 50 to about 300 residues in length.
- compositions including the peptides and peptidomimetic sequences disclosed herein.
- a composition includes a peptide or peptidomimetic sequence and a nucleic acid damaging agent.
- a composition includes a peptide or peptidomimetic sequence and an anti -proliferative agent.
- a composition includes a pharmaceutically acceptable carrier or excipient and a peptide or peptidomimetic sequence and optionally a nucleic acid damaging agent or an anti-proliferative agent.
- methods include administering a nucleic acid damaging agent, a nucleic acid damaging treatment, an anti-proliferative agent, or an anti-proliferative treatment to the subject.
- the agent or treatment comprises a drug (e.g., a
- chemotherapeutic drug such as 5-fluorouracil (5-FU), rebeccamycin, adriamycin (ADR), bleomycin (Bleo), pepleomycin, a cisplatin derivative such as cisplatin (CDDP) carboplatin, picoplatin, nedaplatin, miriplatin, satraplatin, triplatin, lipoplatin, mitaplatin, oxaliplatin, or camptotecin (CPT)), radiation (e.g., UV radiation, IR radiation, or alpha-, beta- or gamma- radiation), a radioisotope (e.g., 1131, 1125, 90Y, 177Lu, 213Bi, or 21 lAt), environmental shock (e.g., hyperthermia).
- 5-FU 5-fluorouracil
- ADR adriamycin
- Bleo bleomycin
- pepleomycin a cisplatin derivative
- the peptides can be of any length.
- the peptides can have from about 5 to 100 or more residues, such as, 5 to 12, 12 to 15, 15 to 18, 18 to 25, 25 to 50, 50 to 75, 75 to 100, or more in length.
- the peptides may include 1- and d-isomers, and combinations of 1- and d-isomers.
- the peptides can include modifications typically associated with post-translational processing of proteins, for example, cyclization (e.g., disulfide or amide bond), phosphorylation, glycosylation, carboxylation, ubiquitination, myristylation, or lipidation.
- Peptides disclosed herein further include compounds having amino acid structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues, so long as the mimetic has one or more functions or activities.
- the compounds disclosed herein therefore include “mimetic” and "peptidomimetic” forms.
- mimetic and “peptidomimetic” refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics of the peptides.
- the mimetic can be entirely composed of synthetic, non-natural amino acid analogues, or can be a chimeric molecule including one or more natural peptide amino acids and one or more non-natural amino acid analogs.
- the mimetic can also incorporate any number of natural amino acid conservative substitutions as long as such substitutions do not destroy the mimetic's activity.
- routine testing can be used to determine whether a mimetic has the requisite activity, e.g., that it has detectable cell cycle G2 checkpoint abrogating activity.
- a mimetic when administered to a subject or contacted on a cell, that detectably disrupts the G2 cell cycle checkpoint, would therefore have G2 checkpoint abrogating activity.
- Peptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
- a polypeptide can be characterized as a mimetic when one or more of the residues are joined by chemical means other than an amide bond.
- Individual peptidomimetic residues can be joined by amide bonds, non-natural and non- amide chemical bonds other chemical bonds or coupling means including, for example, glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, ⁇ , ⁇ '- dicyclohexylcarbodiimide (DCC) or ⁇ , ⁇ '-diisopropylcarbodiimide (DIC).
- amide bonds non-natural and non- amide chemical bonds other chemical bonds or coupling means including, for example, glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, ⁇ , ⁇ '- dicyclohexylcarbodiimide (DCC) or ⁇ , ⁇ '-diisopropylcarbodiimide (DIC).
- DCC dicyclohexylcarbodiimide
- DIC ⁇ , ⁇ '-diisopropylcarbodiimide
- a peptide can be characterized as a mimetic by containing one or more non- natural residues in place of a naturally occurring amino acid residue.
- Non-natural residues are known in the art.
- Particular non-limiting examples of non-natural residues useful as mimetics of natural amino acid residues are mimetics of aromatic amino acids include, for example, D- or L- naphylalanine; D- or L-phenylglycine; D- or L-2 thieneylalanine; D- or L-l, -2,3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)- alanine; D- or L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)-phenylglycine; D-(trifluoromethyl)- phenyl
- Aromatic rings of a non-natural amino acid that can be used in place of a natural aromatic rings include, for example, thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.
- Mimetics of acidic amino acids can be generated by substitution with non-carboxylate amino acids while maintaining a negative charge; (phosphono) alanine; and sulfated threonine.
- Carboxyl side groups e.g., aspartyl or glutamyl
- Carboxyl side groups can also be selectively modified by reaction with carbodiimides (R'— N— C— N— R') including, for example, l-cyclohexyl-3(2-morpholinyl- (4-ethyl) carbodiimide or l-ethyl-3(4-azonia-4,4-dimetholpentyl) carbodiimide.
- Aspartyl or glutamyl groups can also be converted to asparaginyl and glutaminyl groups by reaction with ammonium ions.
- Mimetics of basic amino acids can be generated by substitution, for example, in addition to lysine and arginine, with the amino acids ornithine, citrulline, or (guanidino)-acetic acid, or (guanidino)alkyl-acetic acid, where alkyl can be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a non-acidic amino acid.
- Nitrile derivative e.g., containing the CN-moiety in place of COOH
- Nitrile derivative can be substituted for asparagine or glutamine.
- Asparaginyl and glutaminyl residues can be deaminated to the corresponding aspartyl or glutamyl residues.
- Arginine mimetics can be generated by reacting arginyl with one or more reagents including, for example, phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, or ninhydrin, optionally under alkaline conditions.
- Tyrosine residue mimetics can be generated by reacting tyrosyl with aromatic diazonium compounds or tetranitromethane.
- N-acetylimidizol and tetranitrom ethane can be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
- Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysinyl with succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino- containing residue mimetics can also be generated by reaction with imidoesters, such as methyl picohnimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid,
- Methionine mimetics can be generated by reaction with methionine sulfoxide.
- Proline mimetics of include, for example, pipecolic acid, thiazolidine carboxylic acid, 3- or 4-hydroxy proline, dehydroproline, 3- or 4-methylproline, and 3,3,-dimethylproline.
- Histidine mimetics can be generated by reacting histidyl with diethylprocarbonate or para-bromophenacyl bromide.
- mimetics include, for example, those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha- amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine; methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C- terminal carboxyl groups.
- One or more residues can also be replaced by an amino acid (or peptidomimetic residue) of the opposite chirality.
- amino acid or peptidomimetic residue
- any amino acid naturally occurring in the L-configuration (which can also be referred to as R or S, depending upon the structure of the chemical entity) can be replaced with the same amino acid or a mimetic, but of the opposite chirality, referred to as the D- amino acid, but which can additionally be referred to as the R- or S-form.
- Peptides and peptidomimetics further include modified forms of the sequences set forth herein, provided that the modified form retains, at least a part of, the function of the unmodified or reference peptide or peptidomimetic.
- a modified peptide or peptidomimetic will retain at least a part of cell proliferative inhibiting or G2 abrogating activity, but may have increased or decreased cell proliferative inhibiting or G2 abrogating activity relative to reference peptide or peptidomimetic.
- Modified peptides and peptidomimetics can have one or more amino acid residues substituted with another residue, added to the sequence or deleted from the sequence.
- the modified peptide or peptidomimetic has one or more amino acid substitutions, additions or deletions (e.g., 1-3,3-5, 5-10 or more).
- the substitution is with an amino acid or mimetic whose side chain occupies a similar space with the reference amino acid or mimetic (the amino acid or mimetic that is being substituted).
- the substitution is with a non-human amino acid which is structurally similar to the human residue.
- the substitution is a conservative amino acid substitution.
- similar space means a chemical moiety that occupies a three- dimensional space similar in size to a reference moiety. Typically, a moiety that occupies a similar space will be similar in size to the reference moiety.
- An amino acid or mimetic that "occupies a similar side chain space” has a side chain that occupies a three-dimensional space similar in size to the reference amino acid or mimetic.
- d-(Phe-2,3,4,5,6-F), l-(Phe-2,3 ,4,5,6-F), d-(Phe-3,4,5F), l-(Phe-3,4,5F), d-(Phe-4CF 3 ) or l-(Phe-4CF 3 ), are (1 or d-Phe- 2R1,3R2,4R3,5R4,6R5) where R1,R2,R3,R4,R5 can be chloride, bromide, fluoride, iodide, hydrogen, hydrogen oxide or absent.
- fluoride which has a size of about 1 Angstrom
- similar space may be absence of a moiety.
- substitution means the replacement of one amino acid by a biologically, chemically or structurally similar residue.
- Biologically similar means that the substitution is compatible with biological activity, e.g., anti-cell proliferative or G2 abrogating activity.
- Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or having similar size.
- Chemical similarity means that the residues have the same charge or are both hydrophilic or hydrophobic.
- Particular examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, and the like.
- Peptides and peptidomimetics therefore include peptides and peptidomimetics having a sequence that is not identical to a sequence of peptides and peptidomimetics sequences set forth in Table 1.
- a peptide or peptidomimetic has a sequence having 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more identity with a sequence set forth in Table 1.
- the identity is over a defined area of the sequence, e.g., the amino or carboxy terminal 3-5 residues.
- the peptides and peptidomimetics can be produced and isolated using any method known in the art.
- Peptides can be synthesized, whole or in part, using chemical methods known in the art (see, e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; and Banga, A. K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, Pa.).
- Peptide synthesis can be performed using various solid-phase techniques (see, e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the manufacturer's instructions.
- Modified peptides can be further produced by chemical modification methods (see, for example, Belousov (1997) Nucleic Acids Res. 25:3440- 3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; and Blommers (1994) Biochemistry 33:7886-7896).
- Peptides can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, or to identify and isolate antibodies or antibody- expressing B cells.
- Domains facilitating detection and purification include, for example, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals; protein A domains that allow purification on immobilized immunoglobulin; and the domain utilized in the FLAGSTM extension/affinity purification system (Immunex Corp, Seattle, Wash.)
- metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals
- protein A domains that allow purification on immobilized immunoglobulin
- the domain utilized in the FLAGSTM extension/affinity purification system Immunex Corp, Seattle, Wash.
- the inclusion of a cleavable linker sequence such as Factor Xa or enterokinase (Invitrogen, San Diego Calif.) between a purification domain and the peptide can be used to facilitate peptide purification.
- an expression vector can include a peptide- encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34: 1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-14).
- the histidine residues facilitate detection and purification of the fusion prtein while the enterokinase cleavage site provides a means for purifying the peptide from the remainder of the fusion protein.
- Technology pertaining to vectors encoding fusion proteins and application of fusion proteins is known in the art (see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53).
- nucleic acids encoding the peptides disclosed herein.
- a nucleic acid encodes peptide sequences herein having a length of about 8 to 12, 12 to 15, 15 to 18, 15 to 20, 18 to 25, 20 to 25, 25 to 35, 25 to 50 or 50 to 100 amino acids or more in length.
- the terms "nucleic acid” and “polynucleotide” are used interchangeably herein to refer to all forms of nucleic acid, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- the nucleic acids can be double, single strand, or triplex, linear or circular Nucleic acids include genomic DNA, cDNA, and antisense.
- RNA nucleic acid can be spliced or unspliced mRNA, rRNA, tRNA or antisense (e.g., RNAi).
- Nucleic acids include naturally occurring, synthetic, as well as nucleotide analogues and derivatives. Such altered or modified polynucleotides include analogues that provide nuclease resistance, for example.
- Nucleic acid lengths also can be less than the exemplified peptide sequences. For example, a subsequence of any of the peptide sequences can encode a peptide having anti-proliferative or G2 abrogating activity.
- Nucleic acid can be produced using any of a variety of well known standard cloning and chemical synthesis methods and can be altered intentionally by site-directed mutagenesis or other recombinant techniques known to those skilled in the art. Purity of polynucleotides can be determined through sequencing, gel electrophoresis and the like.
- Nucleic acids may be inserted into a nucleic acid construct in which expression of the nucleic acid is influenced or regulated by an "expression control element," the combination referred to as an "expression cassette.”
- expression control element means one or more sequence elements that regulates or influences expression of a nucleic acid sequence to which it is operatively linked.
- An expression control element operatively linked to a nucleic acid sequence controls transcription and, as appropriate, translation of the nucleic acid sequence.
- operatively linked refers to a functional juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- expression control elements are juxtaposed at the 5' or at the 3' ends of the gene but can also be intronic. Promoters are generally positioned 5' of the coding sequence.
- a “promoter” is meant a minimal sequence element sufficient to direct transcription.
- Expression control elements include promoters, enhancers, transcription terminators, gene silencers, a start codon (e.g., ATG) in front of a protein-encoding gene.
- Expression control elements activate constitutive transcription, inducible transcription (i.e., require an external signal for activation), or derepress transcription (i.e., a signal turns transcription off; removing the signal activates transcription).
- Expression cassettes can also include control elements sufficient to render gene expression controllable for specific cell-types or tissues (i.e., tissue-specific control elements).
- Nucleic acids may be inserted into a plasmid for propagation into a host cell and for subsequent genetic manipulation.
- a plasmid is a nucleic acid that can be stably propagated in a host cell; plasmids optionally contain expression control elements in order to drive expression of the nucleic acid encoding peptide in the host cell.
- the term "vector" is used herein synonymously with a plasmid and may also include an expression control element for expression in a host cell. Plasmids and vectors generally contain at least an origin of replication for propagation in a cell and a promoter. Plasmids and vectors are therefore useful for genetic manipulation of peptide encoding nucleic acids, for producing peptides, and for expressing the peptides in host cells or whole organisms, for example.
- Peptides may therefore be expressed in bacterial systems using constitutive promoters such as T7, or inducible promoters such as pL of bacteriophage ⁇ , plac, ptrp, ptac (ptrp-lac hybrid promoter); in yeast systems using constitutive promoters such as ADH or LEU2 or an inducible promoter such as GAL (see, e.g., Ausubel et al., In: Current Protocols in Molecular Biology, Vol. 2, Ch. 13, ed., Greene Publish. Assoc. & Wiley Interscience, 1988; Grant et al. Methods in Enzymology, 153:516 (1987), eds.
- constitutive promoters such as T7, or inducible promoters such as pL of bacteriophage ⁇ , plac, ptrp, ptac (ptrp-lac hybrid promoter); in yeast systems using constitutive promoters such as ADH or LEU2
- Peptide expression systems further include vectors designed for in vivo use including adenoviral vectors (U.S. Pat. Nos. 5,700,470 and 5,731 , 172), adeno-associated vectors (U.S. Pat. No. 5,604,090), herpes simplex virus vectors (U.S. Pat. No. 5,501 ,979) and retroviral vectors (U.S. Pat. Nos. 5,624,820, 5,693,508 and
- Bovine papilloma virus has also been employed in gene therapy (U.S. Pat. No. 5,719,054).
- Such gene therapy vectors also include CMV based vectors (U.S. Pat. No. 5,561,063).
- CBP501 (SEQ ID NO:80) is an anti-cancer drug candidate that was investigated in two randomized Phase II clinical trials for patients with non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).
- NSCLC non-squamous non-small cell lung cancer
- MPM malignant pleural mesothelioma
- CBP501 has been shown to have two mechanisms of action, namely calmodulin modulation and G2 checkpoint abrogation.
- a biomarker to predict sensitivity to CBP501 is disclosed herein.
- NSCLC cell lines were classified into two subgroups, CBP501 sensitive and insensitive, by quantitatively analyzing the cis-diamminedichloro-platinum (II) (CDDP)-enhancing activity of CBP501 through treatments with short term (1 hour) co-exposure to CDDP and CBP501 or to either alone.
- CDDP cis-diamminedichloro-platinum
- Microarray analysis was performed on these cell lines to identify gene expression patterns that correlated with CBP501 sensitivity. It was found that multiple Nuclear factor erythroid-2 related factor2 (Nrf2) target genes showed high expression in CBP501 -insensitive cell lines.
- Nrf2 Nuclear factor erythroid-2 related factor2
- Nrf2 transcriptional factor is a potential candidate as a biomarker for resistance to CBP501.
- Examples include some tyrosine kinase inhibitors, including gefitinib and erlotinib, that target epidermal growth factor receptor (EGFR) in NSCLC and for which efficacy depends on the presence of particular EGFR mutations (1, 2); Crizotinib, which is highly effective when NSCLC cells harbor the EML4-ALK fusion gene (3); and the BRAF inhibitor Vemurafenib, which is highly effective when melanoma cells carry the V600E mutation of BRAF (4).
- EGFR epidermal growth factor receptor
- Nrf2 is a transcription factor that regulates the expression of many antioxidant genes, including those related to glutathione synthesis (1 1). In tumorigenesis, expression of particular oncogenic alleles of Kras, BRAF and Myc increases the levels of intracellular antioxidants by inducing Nrf2 expression ( 12). Nrf2 also regulates the expression of genes related to drug detoxification and transport (13).
- This Example focuses on CBP501 's effect on promoting CDDP uptake rather than G2 checkpoint abrogation by examining cells only upon short-term exposure to CBP501 and CDDP.
- Twenty-eight NSCLC cell lines were quantitatively defined as sensitive or insensitive to CBP501 by analyzing their response to a short (lh) co-exposure with CDDP and CBP501 as compared with either drug alorte.
- Comprehensive gene expression analysis was performed on these cell lines to identify the sensitivity markers for this MOA of CBP501.
- Multiple genes regulated by the Nrf2 transcription factor were identified as having high expression in CBP501 insensitive cell lines. Additionally, knock-down of Nrf2 by using Nrf2 sh-RNA revealed that Nrf2 expression is required for resistance to CBP501.
- RPMI1640 supplemented with 2mM L-glutamine (Invitrogen) for NCI-H727; RPMI1640 supplemented with 4.5 g/L D-glucose (Sigma-Aldrich), lOmM HEPES (Sigma-Aldrich) and ImM sodium pyruvate (Sigma-Aldrich) for NCI-H358, NCI-H520, NCI-H23, NCI-H647 and NCI-H838; Ham's F12K (Sigma-Aldrich) for A549.
- CDDP was purchased from Sigma- Aldrich.
- Sulforaphane (SFN) was purchased from Sigma-Aldrich. All NSCLC cell lines were purchased from ATCC and STR analysis had been performed by ATCC to authenticate the identity of each cell line. All cell lines were used within three months after thawing.
- Cell cycle analysis Cells were plated in 24-well plates and incubated for 24 hours. The cells were treated with or without CDDP plus or minus CBP501 at the indicated concentration for the indicated times. The cells were harvested and stained with Krishan's solution (0.1% sodium citrate, 50 ⁇ g/ml propidium iodide, 20 ⁇ g/ml RNase A, 0.5% NP-40). Stained cells were analyzed by FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) using CELLQuest software (Becton Dickinson).
- Antibodies were purchased from the indicated sources: anti-NROB l, anti- Grx, anti-Prx, anti-yGCSc, anti-yGCSm and anti-Gpxl (SantaCruz, Dallas, TX); anti-MLC, anti-G6PD, anti-ABCC2, anti-KEAPl, anti-BACHl, anti-Trxl, anti-SODl, anti-HOl, anti- NQOl, anti-IQGAP l and anti-ATM (Cell Signaling Technology, Beverly, MA); anti-GSR, anti-A RIC I, anti-AKRlC3, anti-AKRIB lO and anti-Nrf2 (Epitomics, San Francisco, CA).
- Nrf2 shRNA lentivirus particles and Control shRNA lentivirus particles were purchased from SantaCruz. Lentivirus infection was performed according to manufacturer's instructions. Cells (50% confluence) were treated with 5 ⁇ g/ml Polybrene (SantaCruz) prior to virus infection. One day after addition of virus, the cells were transferred to fresh medium and cells were selected by treatment with Puromycin (SantaCruz).
- the lysates were clarified by centrifugation (20600g, 4°C), and the supematants were assayed for protein content using the detergent-compatible protein assay kit (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
- the whole cell lysates 60 ⁇ g were run on 10-12% SDS-PAGE. Protein from each gel was transferred onto a polyvinylidene difluoride, (PVDF), membrane (Bio-Rad).
- the membrane was blocked at room temperature for 1 h in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl and 0.05% Tween-20) containing 1 % Block Ace (DS pharma) and incubated with primary antibody overnight at 4 °C.
- the membrane was incubated further with anti-peroxtdase conjugated secondary antibody (Cell Signaling) for one hour at room temperature after washing, and the signals were detected using the enhanced chemiluminescence detection system (ECL Advance Western Blotting Detection Kit, GE Healthcare). Detected bands were quantified using Lumino-mater LAS-4000 instrument (Fujifilm, Tokyo, Japan).
- CBP501 sensitizes tumor cells to CDDP, as shown by various methods including colony formation assays, in vitro viability assays, and flow-cytometry analysis, which measures systematic changes in cell cycle distribution.
- colony formation assays in vitro viability assays
- flow-cytometry analysis which measures systematic changes in cell cycle distribution.
- the results between the different methods correlate well (8, 9) and differential sensitivity to CBP501 varies consistently for different cell lines (9).
- the NCI-H 1437 cell line did not exhibit any detectable shift in the dose-response curve of CDDP caused by CBP501 (Fig.lE-H).
- twelve NSCLC cell lines were classified as being either, CBP501-sensitive or CBP501-insensitive. Cell lines that shifted the curve two fold or more were classified as CBP501 sensitive cells and those that shifted the curve less than two fold were classified as CBP501 insensitive (Table 1). Classification of CBP501 sensitivity in NSCLC cell lines.
- Nrf2 target genes might have up-regulated expression in CBP501 -insensitive cell lines
- GSR Glutathione reductase
- G6PD Glucose-6-phosphate dehydrogenase
- ABCC2 ATP-binding cassette sub- familyC member2
- ACR1C 1 Aldo-keto reductase family 1C 1
- AKR1 C3 Aldo-keto reductase family 1C 1
- Nrf2 16-20
- Nrf2 knock-down cell line of HI 703 which is sensitive to CBP501 was produced (Fig.4B).
- CBP501 , CDDP and SFN a known Nrf2 activator (17) was studied.
- SFN caused Nrf2 protein levels to increase in a dose dependent manner in the cells transfected with a control shRNA.
- SFN did not cause a similar increase the levels of Nrf2 protein in cells transfected with Nrf2 shRNA.
- Addition of SFN attenuated CBP501 's effect in cells transfected with control shRNA (Fig.4C, D). However, the effect of SFN was abrogated in the Nrf2 knock-down strain
- Nrf2 knock-down was investigated. Nrf2 knock-down was found to cause reduced levels of expression for Nrf2 knock-down
- FIG.5A A R1C3, G6PD and GSR (Fig.5A).
- CBP501 was found to increase the effects of CDDP on changes in the cell cycle distribution of subGl and G2-M, reversing the initial CBP501-insensitivity.
- a cell line transfected with control shRNA showed no difference in CDDP activity with or without CBP501 (Fig.5B, C).
- Nrf2 protein is a candidate marker to predict resistance to CBP501 ; Nrf2 targets, at either the protein or mRNA level, are additional candidate markers
- Nrf2 may possibly predict resistance to CBP501
- the general reliability of these predictive markers for CBP501 -sensitivity remained to be established.
- the combination effect of CBP501 and CDDP in sixteen additional NSCLC cell lines, classifying each as CBP501 sensitive or insensitive by the prior criteria was analyzed (Table 2). Classification of CBP501 sensitivity in additional NSCLC cell lines.
- CBP501 has at least two mechanisms of action as an anti- cancer drug candidate (8, 9).
- G2 checkpoint abrogation occurs for treatments of longer duration and at higher doses (8).
- a second anti-cancer activity of CBP501 the enhancement of CDDP uptake through the binding to calmodulin, occurs for treatments of shorter duration and at lower doses (9).
- focus is placed on the latter effect and characterized the CBP501 sensitivity of many different NSCLC cell lines by treating cells for shorter duration with lower doses of CBP501.
- CBP501 sensitivity was predicted by identifying major differences in gene expression profiles between CBP501 sensitive and insensitive cell lines, as determined by microarray analysis. This comprehensive analysis of gene expression initially led to several candidates for predictive markers of CBP501 sensitivity. Increased expression of genes from a common transcriptional pathway regulated by Nrf2 was identified as a possible indicator of insensitivity to CBP501.
- Nrf2 is known to be a key transcription factor for genes related to cytoprotective function (22-26). Under homeostatic conditions, Nrf2 is maintained at very low intracellular concentration by the proteasomal degradation system through its association with Kelch-like ECH associated protein 1 (Keapl) and the Cul3 E3 ligase (27-30). It was found that Nrf2 protein expression levels were higher in CBP501 insensitive cell lines than in CBP501 -sensitive cell lines. However, Keapl expression levels did not correlate as well with sensitivity to CBP501 (Fig.2B). This result might indicate that the ability of Nrf2 protein to degrade under homeostatic conditions varies among different cell lines.
- Kelch-like ECH associated protein 1 Kelch-like ECH associated protein 1
- Cul3 E3 ligase 27-30
- Keapl mutations are present in a series of NSCLC cell lines that were used in this Example (Table 3 below). Keapl mutations had a tendency to be present in CBP501 -insensitive cell lines. This indicates that Keapl mutation status is a useful indicator of resistance to CBP501. The role of each mutation type will be further verified.
- Nrf2 target genes Differential expression of several Nrf2 target genes at the RNA or protein level was identified as a means to identify candidates for markers to predict CBP501 insensitivity. Of these initial candidates, G6PD, GSR and AKR1C3 showed significant differences in both mRNA and protein expression levels between CBP501 sensitive and insensitive cell lines. Regulation of the expression of these identified genes was recognized as being under the common control of Nrf2 binding elements called AREs (antioxidant response elements) (23). Several known transcription factors can antagonize Nrf2 by competing for interaction at AREs (antioxidant response elements) (23).
- AREs antioxidant response elements
- AREs include the small MAF proteins, BACHl , c-FOS and FRAl (23, 34, 35). These transcriptional regulators might be involved in controlling the differential expression of different Nrf2 target genes.
- BACHl protein is one for which expression in NSCLC cell lines appears to increase in CBP501 sensitive cell lines (Fig.2B).
- Nrf2 participates in a diverse spectrum of different biological phenomena, including metabolism, the xenobiotic response, and the antioxidant response, by inducing the expression of numerous genes (22-26). For instance, inducing the expression of G6PD and GSR elevates glutathione levels and this leads to the antioxidant response (36, 37). AKR1C3 can mediate pathways leading to the synthesis of testosterone and to prostaglandin formation (38, 39).
- Nrf2 knock-down experiments indicate that Nrf2 might modulate the CBP501 sensitivity, there is still no definitive answer about which Nrf2 target gene or phenomena directly affect CBP501 -sensitivity.
- One or several Nrf2 target genes might be involved in determining cell sensitivity to CBP501 's effects on CDDP uptake.
- IHC immunohistochemistry
- MacLeod AK McMahon M. Plummer SM. Higgins LG. Penning TM. Igarashi K. et al.
- Keapl -BTB protein is an
- Oxidative stress sensor Keapl functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24:7130-9
- Keap l is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24: 10941 -53
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Disclosed herein, inter alia, are methods and uses for treating a cancer in a subject. In various embodiments, a method or use includes measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer, then comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene. If the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene, the subject having the cancer may be or is treated with a peptide or peptidomimetic sequence set forth herein, such as P1, P2, P3, P4, P5, P6 (SEQ ID NO:1) or P6, P5, P4, P3, P2, P1 (SEQ ID NO:2), e.g., CBP501.
Description
E RIP ION
NRF2-BASED CANCER TREATMENT AND DETECTION METHODS AND USES
RELATED PATENT APPLICATION
[OOOlj This patent application claims the benefit of U.S. Provisional Application Nos 62/002,076 filed May 22, 2014 and 62/036,476, August 12, 2014, which are incorporated herein by reference in their entirety.
INTRODUCTION
[0002] The cell cycle comprises S phase (DNA replication), M phase (mitosis), and two gap phases (Gl and G2 phases) between S and M phases. Checkpoints in the cell cycle ensure accurate progression, such as monitoring the state of DNA integrity, DNA replication, cell size, and the surrounding environment (Mailer, J. L. Curr. Opin. Cell Biol., 3:26 (1991)). It is especially important for multi-cellular organisms to maintain integrity of genome, and there are multiple checkpoints that monitor the state of genome. Among them are Gl and G2 checkpoints existing before DNA replication and mitosis, respectively. It is also important to correct DNA damage before entering S phase, because once damaged DNA is replicated it often gives rise to mutations (Hartwell, L. Cell, 71 : 543 (1992)). Progression through G l and G2 checkpoints without repairing extensive DNA damage induces apoptosis and/or catastrophe.
[0003] Most cancer cells carry abnormalities in Gl checkpoint-related proteins such as p53, Rb, MDM-2, pl6INK4 and pl9ARF (Levine, A. J. Cell, 88:323 (1997)). Alternatively, mutations can cause over-expression and/or over activation of oncogene products, e.g., Ras, MDM-2 and cyclin D, which reduce the stringency of Gl checkpoint. In addition to these mutations, excessive growth factor signaling can be caused by the over expression of growth factors and can reduce the stringency of Gl checkpoint. Together with loss and gain-of- function mutations, continuous activation of growth factor receptors or downstream signal- transducing molecules can cause cell transformation by overriding the Gl checkpoint.
Abrogated G l checkpoint contributes to higher mutation rates and the many mutations observed in cancer cells. As a result, most cancer cells depend on G2 checkpoint for survival against excessive DNA damage (O'Connor and Fan, Prog. Cell Cycle Res., 2: 165 (1996)).
[0004] The mechanism that promotes the cell cycle G2 arrest after DNA damage is believed to be conserved among species from yeast to human. In the presence of damaged DNA,
Cdc2/Cyclin B kinase is kept inactive because of inhibitory phosphorylation of threonine- 14 and tyrosine-15 residues on Cdc2 kinase or the protein level of Cyclin B is reduced. At the onset of mitosis, the dual phosphatase Cdc25 removes these inhibitory phosphates and
thereby activates Cdc2/Cyclin B kinase. The activation of Cdc2/Cyclin B is equivalent to the onset of M phase.
[0005] In fission yeast, the protein kinase Chkl is required for the cell cycle arrest in response to damaged DNA. Chkl kinase acts downstream of several rad gene products and is modified by the phosphorylation upon DNA damage. The kinases Rad53 of budding yeast and Cdsl of fission yeast are known to conduct signals from unreplicated DNA. It appears that there is some redundancy between Chkl and Cdsl because elimination of both Chkl and Cds l culminated in disruption of the G2 arrest induced by damaged DNA. Interestingly, both Chk l and Cdsl phosphorylate Cdc25 and promote Rad24 binding to Cdc25, which sequesters Cdc25 to cytosol and prevents Cdc2/Cyclin B activation. Therefore Cdc25 appears to be a common target of these kinases implying that this molecule is an indispensable factor in the G2 checkpoint.
[0006] In humans, both hChkl, a human homologue of fission yeast Chkl, and
Chk2/HuCdsl, a human homologue of the budding yeast Rad53 and fission yeast Cdsl, phosphorylate Cdc25C at serine-216, a critical regulatory site, in response to DNA damage. This phosphorylation creates a binding site for small acidic proteins 14-3-3s, human homologues of Rad24 and Rad25 of fission yeast. The regulatory role of this phosphorylation was clearly indicated by the fact that substitution of serine-216 to alanine on Cdc25C disrupted cell cycle G2 arrest in human cells. However, the mechanism of G2 checkpoint is not fully understood.
SUMMARY
[0007] Disclosed herein, in various embodiments, are methods for treating a cancer in a subject. In one embodiment, a method comprises a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene; and c) treating the subject having the cancer with PI, P2, P3, P4, P5, P6 (SEQ ID NO: l) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2) (e.g., CBP501) if expression of the NRF2, or the NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene. In another embodiment, a method comprises a) screening for a normal or a functional KEAP 1, or
a mutation that reduces or decreases activity, function or expression of KEAP 1 in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the presence of a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and b) treating the subject having the cancer with PI , P2, P3, P4, P5, P6 (SEQ ID NO: 1) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2) (e.g., CBP501) if the subject has a normal or a functional KEAP 1 or does not have a mutation that reduces or decreases activity, function or expression of KEAP 1.
[0008] Disclosed herein, in various embodiments, are methods for treating a cancer in a subject. In one embodiment, a method comprises a) identifying and/or selecting a subject with a cancer in which NRF2 expression or NRF2 target gene expression in the subject is less than a baseline or reference amount of NRF2 or NRF2 target gene, or where the subject has a normal or a functional KEAP 1 or lacks a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) treating the cancer in the subject with a peptide or peptidomimetic set forth herein (e.g., CBP501 ) as if the NRF2 or the NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene, or if the subject has a normal or a functional KEAP 1 or does not have a mutation that reduces or decreases activity, function or expression of KEAP 1. In another embodiment, a method comprises, a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene and c) selecting the subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
[0009] Further disclosed herein are methods for selecting and/or identifying a subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501). In one
embodiment, a method includes a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) selecting the subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if normal or a functional KEAP 1 is present or a mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or not present. In another embodiment, a method includes a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or NRF2
target gene in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 in order to determine if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene and c) identifying the subject as a candidate for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
[0010] In embodiments for screening or for identifying a candidate subject for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501), certain aspects can sometimes comprise, a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and b) identifying the subject as a candidate for cancer treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the normal or a functional KEAP 1 is present, or a mutation mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or not present.
[0011] Additionally disclosed herein are methods for characterizing a cancer as more responsive or less responsive to treatment with a peptide or peptidomimetic as set forth herein (e.g.,
CBP501). In one embodiment, a method includes a) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or NRF2 target gene of cells of a cancer, and determining the amount of NRF2 or NRF2 target gene expressed, b) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a predetermined value for NRF2 or NRF2 target gene in order to determine if the amount of NRF2 or NRF2 target gene is less or greater than the predetermined value for NRF2 or NRF2 target gene and c) characterizing the cancer as more responsive or less responsive to treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the NRF2 or NRF2 target gene expression is less than or greater than the predetermined value for NRF2 or NRF2 target gene. In another embodiment, a method includes a) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 and/or b) characterizing the cancer as more responsive or less responsive to treatment with a peptide or peptidomimetic as set forth herein (e.g., CBP501) if the normal or a functional KEAP 1 is present or absent, or a mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or present.
[0012] In various embodiments a NRF2 target gene is any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase familylCl (AKR1C1), Aldo-keto reductase familylC3
(AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) and/or Glutathione peroxidasel (GPX1).
[0013] In some embodiments a baseline or reference level or predetermined value is determined by expression in cancer cells responsive to a peptide or peptidomimetic as set forth herein (e.g., CBP501) treatment compared to cancer cells less-responsive to a peptide or peptidomimetic (e.g., CBP501) as set forth herein treatment.
[0014] In some embodiments a sample comprises a biological sample. In certain aspects, a sample can comprise a cell, tissue or organ (e.g., lung) biopsy, or a blood or serum sample.
[0015] In certain aspects a subject is a mammal. The mammal can be a human. In some aspects a subject is a human.
[0016] In various embodiments, expression is measured by a quantitative assay. In some aspects expression is measured with, or detected by contact with an analyte that detects an NRF2 protein or a protein encoded by an NRF2 target gene, or detects KEAP 1 protein or target gene, or a mutation that reduces or decreases activity, function or expression of KEAP 1. In some embodiments expression is measured or detected by contact with an analyte that detects an NRF2 transcript, or the transcript of an NRF2 target gene, or by sequencing a nucleic acid that comprises KEAP 1 , or a mutation that reduces or decreases activity, function or expression of KEAP 1 . In some embodiments expression is measured or detection is by an immunoassay. In some embodiments expression is measured or detection is by an antibody immunoassay. In some embodiments, expression is measured or detection is by a Western blot, ELISA, Northern blot, immunohistochemistry or immunocyotchemistry. In certain embodiments expression is measured or detection is by determining cDNA of NRF2 or cDNA of NRF2 target gene. In some aspects, expression is measured or detection is by reverse transcription of NRF2 RNA or NRF2 target gene RNA and polymerase chain reaction (RT-PCR) of NRF2 cDNA or NRF2 target gene cDNA, or reverse transcription of KEAP 1 RNA or KEAP 1 gene and polymerase chain reaction (RT-PCR) of KEAP 1 cDNA.
[0017] In certain embodiments, a peptide or peptidomimetic (e.g., CBP501) comprises a salt or a pro-drug thereof, or a salt of a pro-drug thereof. In various aspects a salt comprises a sodium, calcium, magnesium, nitrate, potassium, phosphate, sulfonate, fumarate, citrate, carbonate, ascorbate, succinate, trifluoroacetate or acetate salt.
[0018] In some embodiments, a method described herein comprises administering a G2 checkpoint inhibitor agent (e.g., a peptide or peptidomimetic such as CBP501). In some embodiments, a method described herein comprises administering a calmodulin binding agent.
In some embodiments, a method described herein includes administering a nucleic acid damaging agent to the subject (e.g., a molecule that binds to or intercalates in DNA).
[0019] In some embodiments, a method described herein comprises administering a peptide or peptidomimetic (e.g., CBP501), a G2 checkpoint inhibitor agent, a calmodulin binding agent or a nucleic acid damaging agent to the subject 1, 2, 3, 4, 5, or more times, alone, or in any combination.
[0020] In certain aspects a cancer comprises a lung cancer (NSCLC).
[0021] Moreover disclosed herein are a population of cancer cells, wherein the cells are fixed or immobilized on a substrate and the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or KEAP 1 protein or gene. In some embodiments, a population of cancer cells obtained from a subject are fixed or immobilized on a substrate and the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or KEAP 1 protein or gene. In certain aspects, the reagent that detects an NRF2 protein or a protein encoded by an NRF2 target gene or KEAP 1 protein comprises an antibody.
[0022] Still further disclosed herein are a population of cancer cells, wherein the cells are fixed or immobilized on a substrate and the cells have bound thereto a reagent that selectively binds to NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript. In some embodiments, a population of cancer cells obtained from a subject are fixed or immobilized on a substrate and the cells have bound thereto a reagent that selectively binds to an NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript. In certain aspects, the reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene comprises an oligonucleotide or primer.
[0023] NRF2 target genes include any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase family 1C1 (AKRIC I ), Aldo-keto reductase family 1C3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl ), AKR1B10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX1 ). In some aspects, a substrate comprises a glass or plastic plate, slide or chip.
[0024] Still further disclosed herein are compositions comprising nucleic acid isolated, purified or extracted from a population of cancer cells, where the nucleic acid comprises NRF2 gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or a transcript thereof, or binds to KEAP 1 gene or a transcript thereof. Compositions include nucleic acid isolated, purified or extracted from a population of cancer cells, wherein the nucleic acid comprises an
NRF2 target gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or transcript thereof, or binds to KEAP 1 gene or a transcript thereof. In some aspects, a reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene, comprises an oligonucleotide or primer.
[0025] Yet further disclosed herein are compositions comprising protein isolated, purified or extracted from a population of cancer cells, where the protein comprises N F2 protein bound to a reagent that selectively detects NRF2 protein, or KEAP 1 protein bound to a reagent that selectively detects KEAP 1 protein. Compositions include protein isolated, purified or extracted from a population of cancer cells, wherein the protein comprises a protein encoded by an NRF2 target gene bound to a reagent that selectively detects the protein encoded by an NRF2 target gene. In some aspects, a reagent that selectively detects NRF2 protein, or protein encoded by an NRF2 target gene, or KEAP 1 protein comprises an antibody.
[0026] NRF2 target genes include any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase family 1C1 (AKR1C1 ), Aldo-keto reductase familylC3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1 B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX 1). In some aspects, a substrate comprises a glass or plastic plate, slide or chip. DESCRIPTION OF THE DRAWINGS
[0027] Figures 1A-1H show CBP501 sensitivity is characterized in both HI 703 and H1437 NSCLC cell lines by l h co-treatment with CDDP. (Figs. 1A-D) HI 703. (Figs. 1E-H) H1437. (Figs. A, E) Cell cycle distribution change on subGl population by flow-cytometry analysis (n=2). (Figs. IB, F) Gl phase (n=2). (Figs. 1C, G) S phase (n=2). (Figs. ID, H) G2-M phase (n=2). Chi-square tests were performed to compare the change in the cell cycle distribution between CBP501 (SEQ ID NO:80) minus and plus at each CDDP dose point. An asterisk indicates statistical significance (pO.001 ). N.S. = not significant (p>0.05). Error bars indicate the standard deviation from duplicate flowcytometry analyses.
[0028] Figures 2A-2D show microarray gene expression analyses indicating an increase in Nrf2 -dependent gene expression in CBP501 insensitive cell lines. (Fig. 2A) Heat-map display of the expression of isolated genes as determined by microarray analysis. Left panel comprises the CBP501 insensitive cell lines. Right panel comprises the CBP501 sensitive cell lines. Green indicates a low level of expression. Red indicates a high level of expression. Black indicates intermediate levels of expression (a value approx. 5000). Experiments were
performed in triplicate. (Fig. 2B) Western blot analysis for Nrf2 signaling components in NSCLCs. (Fig. 2C) Quantitative analysis of Nrf2 protein levels in NSCLCs (n=3). (Fig. 2D) Western blot analysis for a series of genes initially identified by microarray analysis.
[0029] Figures 3A-3C show a high degree of Nrf2 nuclear localization correlates with high levels of Nrf2 expression. (Fig. 3A) Immunocytochemistry for Nrf2 in NSCLCs. Left panels show Nrf2 in green. Middle panels show Hoechst dye in red. Right panels show the merged images. Scale bar indicates ΙΟΟμιη. (Figs. 3B, C) Quantification of Nrf2 intensities from the five different images from Figure 3A (n=5). (Fig. 3B) Nrf2 intensities in whole cells. (Fig. 3C) Nrf2 intensities in nuclei. Error bars signify standard deviations of Nrf2 intensity as determined from the five different images.
[0030] Figure 4A-D show Nrf2 activating agent Sulforaphane (SFN) cancels the effect of CBP501 ; knock-down of Nrf2 attenuates SFN's effect. (Fig. 4A) Western blot analysis for a series of Nrf2 target proteins in NSCLCs. (Fig. 4B) Confirmation of the efficiency of knockdown by Nrf2 shRNA lentivirus transfection. Upper bands indicated by black arrow head are Nrf2 protein levels. Middle and lower bands indicate internal controls of IQGAP1 and ATM respectively. (Figs. 4C, D) Analysis of cell cycle distribution changes by using Flow- cytometry (n=4). SFN was subjected 24h to HI 703 Control (Ctrl)-sh and Nrf2-sh sub-lines prior to l h treatment of CDDP (2^g/ml)/CBP50 l (Ι μΜ). (Fig. 4C) Whole cell cycle distribution. (Fig. 4D) G2-M phase. An asterisk indicates statistical significance (TTEST; p<0.005). Error bars signify standard deviations as determined from four flowcytometric analyses.
[0031] Figures 5A-C show knock-down of Nrf2 in the CBP501 -insensitive cell line H1437, increases CBP501 sensitivity. (Fig. 5A) Confirmation of knock-down efficiency by Nrf2 shRNA lentivirus infection. Upper bands indicate Nrf2 protein level. Middle three bands are the Nrf2 target molecules AKR1C3, G6PD and GSR respectively. Lower two bands indicate internal controls of IQGAPl and MLC2 alpha respectively. (Fig. 5B) One hour treatment with CDDP in combination with or without CBP501. Cell cycle distribution changes are detected by Flow-cytometry (n=4). The graphs at the left are from the sub-line established by introducing Control (Ctrl)-shRNA into the H1437. The graphs at the right are from the sub- line established by indtroducing Nrf2-shRNA into H1437. Upper graphs indicate the subG l population. Lower graphs indicate the G2-M population. An asterisk indicates statistical significance (TTEST; pO.001). N.S. = not significant (p>0.01); (Fig. 5C) Graphs of the difference analysis for the data from Figure 5B. Blue bars indicate Control (Ctrl)-shRNA
with CBP501 minus the cell line without CBP501. Red bars indicate Nrf2-sh with CBP501 minus the cell line without CBP501. Graph (left) indicates the percentage of cells in subGl . Graph (right) indicates the percentage in G2-M. An asterisk indicates statistical significance (TTEST; pO.001) between red and blue bars. Error bars indicate the standard deviation found from four flowcytometry analyses.
[0032] Figures 6A-E show Nrf2 target genes are good candidates as markers for predicting CBP501 sensitivity using their protein or mRNA expression levels. (Fig. 6A) Heat-map display of isolated gene expression levels, as determined by microarray analysis, in a total of twenty-eight NSCLC cell lines. Left panel comprises the CBP501 insensitive cell lines. Right panel comprises the CBP501 sensitive cell lines. Green indicates a value indicating a low level of expression. Red indicates a high level of expression. Black indicates intermediate levels of expression (numerical value approx. 5000). Experiments performed in triplicate. Percentage of correlation between CBP501 sensitivity and isolated gene expression values are indicated at the right side of the heat-map panel. (Fig. 6B) Western blot analysis for a series of Nrf2 target proteins in NSCLC cell lines extended beyond the original set (Table 2). (Fig. 6C) Quantitative analysis of Nrf2 and A R1 C3 protein levels in NSCLCs from tablet and 2 (n=3). (Fig. 6D) Immunocytochemistry for AKR1C3 in NSCLCs. Upper panels show APCR1C3 in green. Middle panels show Hoechst dye in red. Lower panels show the merged image. Scale bar indicates ΙΟΟμηι. (Fig. 6E) Quantification of the AKR1C3 intensities from C (n=5).
[0033] Figure 7 shows comparative analysis of individual gene expression as in CBP501 insensitive cell lines or the CBP501 sensitive cell lines from Figure 2. Black bars indicate the average values of expression in CBP501 insensitive cell lines. Red bars indicate the average values of expression in CBP501 sensitive cell lines.
[0034] Figures 8A-8B show (Fig. 8A) immunocytochemistry for A R1C1 in NSCLCs. Left panels show A R1 C 1 in a pseudo-color of green. Middle panels show Hoescht in a pseudocolor of red. Right panels show the merged images. Scale bar indicates 100 microns; (Fig. 8B) qualification of AKR1C 1 intensities from Fig. 8A (n = 5).
[0035] Figures 9A-9B show (Fig. 9A) immunocytochemistry for A R1B 10 in NSCLCs. Left panels show AKR1B 10 in a pseudo-color of green. Middle panels show Hoescht in a pseudo-color of red. Right panels show the merged images. Scale bar indicates 100 microns; (Fig. 9B) quatification of AKR1 B 10 intensities from Fig. 9A (n = 5).
DETAILED DESCRIPTION
[0036] In some embodiments, there are provided peptides and peptidomimetics employed in connection with the methods disclosed herein. In one embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO: l) or P6, P5, P4, P3, P2, PI (SEQ ID NO:2). PI is Cha, Nal (2), (Phe-2,3,4,5,6-F),,(Phe-3,4,5F), (Phe-4CF3), an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid (e.g., P4 is Trp), or wherein one or more of P3, P4, P5 is a simple carbon chain (e.g., 1 1-aminoundecanoic acid, 10-aminodecanoic acid, 9- aminononanoic acid, 8-aminocaprylic acid, 7-aminoheptanoic acid, 6-aminocaproic acid, or a similar structure with one or more unsaturated carbon bonds) such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; and P6 is Bpa, Phe4N02, any one amino acid and Tyr (e.g., Ser-Tyr), any one amino acid and Phe (e.g., Ser- Phe), any amino acid, or nothing.
[0037] In another embodiment, a peptide or peptidomimetic sequence includes the following structure: PI , P2, P3, P4, P5, P6 (SEQ ID NO:3); P6, P5, P4, P3, P2, PI (SEQ ID NO:4); PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:5); PI, P2, P3, P4, P5, P6, P12, Pl l, P10, P9, P8, P7 (SEQ ID NO:6); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:7); P6, P5, P4, P3, P2, PI, P12, Pl l, P10, P9, P8, P7 (SEQ ID NO:8); P7, P8, P9, PI O, Pl l, P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:9); P7, P8, P9, P10, PI 1, P12, P6, P5, P4, P3, P2, PI (SEQ ID
NO: 10); P12, PI 1, P10, P9, P8, P7, PI, P2, P3, P4, P5, P6 (SEQ ID NO: l 1); P12, Pl l, P10, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO: 12); P12, PI, P6, P9, P8, P7, P2, PI (SEQ ID NO: 13); P12, Pl l, PIO, P6, P9, P4, P7, P2, PI (SEQ ID NO: 14); PI, P2, P7, P8, P9, P6, Pl l, P12 (SEQ ID NO: 15); or PI , P2, P7, P4, P9, P6, P10, PI 1, P12 (SEQ ID NO:16). PI is Cha, Nal(2), (Phe- 2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, an amino acid that occupies a similar side chain space (e.g. d- or 1-Tyr, d- or 1-Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-
3,4,5F), (Phe-4CF3), or an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P3, P4, P5 is any amino acid (e.g., P4 is Trp), or one or more of P3, P4, P5 is a simple carbon chain (e.g., 1 1-aminoundecanoic acid, 10-aminodecanoic acid, 9-aminononanoic acid, 8- aminocaprylic acid, 7-aminoheptanoic acid, 6-aminocaproic acid, or a similar structure with one or more unsaturated carbon bonds) such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is Bpa, Phe4N02, any one amino acid and Tyr (e.g., Ser-Tyr), any one amino acid and Phe (e.g., Ser-Phe); and at least three of P7, P8, P9, P10, PI 1, P12 are basic amino acids with the rest being any amino acid or absent.
[0038] In a further embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, PIO, PI 1, P12 (SEQ ID NO:17); P12, PI 1, P10, P9, P8, P7, P6, P5, P4, P3, P2, P1(SEQ ID NO: 18); P12, Pl l, P10, P6, P9, P4, P7, P2, P1(SEQ ID NO: 19); or PI , P2, P7, P4, P9, P6, P10, PI 1, P12 (SEQ ID NO:20). PI is Cha, Nal(2), (Phe-
2,3,4,5, 6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), an amino acid that occupies a similar side chain space (e.g., Tyr or Phe), or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P3, P4, P5 are any amino acid (e.g., P4 is Trp), or one or more of P3, P4, P5 is a simple carbon chain (e.g., aminoundecanoic acid or 8- aminocaprylic acid) such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is Bpa, Phe4N02, any one amino acid and Tyr (e.g., Ser-Tyr), any one amino acid and Phe (e.g., Ser-Phe), any amino acid, or nothing; and at least three of P7, P8, P9, P10, PI 1, P12 are basic amino acids with the rest being any amino acid or absent.
[0039] In an additional embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO:21) or P6, P5, P4, P3, P2, PI (SEQ ID NO:22). PI is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe; P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe;
P3 is Ser, Arg, Cys, Pro, or Asn; P4 is Τφ; P5 is Ser, Arg, or Asn; or P3, P4, P5 is a single aminoundecanoic acid or a single 8-aminocaprylic acid; and P6 is Bpa, Phe4N02, (Ser-Tyr), or (Ser-Phe).
[0040] In yet another embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:23); PI, P2, P3, P4, P5, P6, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:24); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:25); P6, P5, P4, P3, P2, PI, P12, PI 1, PIO, P9, P8, P7 (SEQ ID NO:26); P7, P8, P9, P10, Pl l , P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:27); P7, P8, P9, PI 0, PI 1, P12, P6, P5, P4, P3, P2, PI (SEQ ID NO:28); P12, Pl l , P10, P9, P8, P7, PI, P2, P3, P4, P5, P6 (SEQ ID NO:29); P12, PI 1, P10, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:30); P12, PI 1, P6, P9, P8, P7, P2, PI (SEQ ID NO:31); P12, PI 1, PIO, P6, P9, P4, P7, P2, PI (SEQ ID NO:32); PI, P2, P7, P8, P9, P6, PI 1, P12 (SEQ ID NO:33); or PI, P2, P7, P4, P9, P6, PIO, PI 1 , P12 (SEQ ID NO:34). PI is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe; P2 is Cha, Nal(2), (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3), Bpa, Phe4N02, Tyr, or Phe; P3 is Ser, Arg, Cys, Pro, or Asn; P4 is Trp; P5 is Ser. Arg, or Asn; or P3, P4, P5 is a single aminoundecanoic acid or a single 8-aminocaprylic acid; P6 is Bpa, Phe4N02, (d-Ser-d-Tyr), or (d-Ser-d-Phe); and at least three of P7, P8, P9, PIO, PI 1, P12 are Arg or Lys with the rest being any amino acid or absent.
[0041] In still another embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, Pl l, P12 (SEQ ID NO:35); P12, Pl l, P10, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:36); P12, PI 1, P10, P6, P9, P4, P7, P2, PI (SEQ ID NO:37); or PI, P2, P7, P4, P9, P6, P10, PI 1 , P12 (SEQ ID NO:38). PI is Cha, or Nal(2); P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F), (Phe-4CF3); P3 is Ser; P4 is Trp; P5 is Ser or Asn; P6 is Bpa, Phe4N02, (Ser-Tyr), or (Ser-Phe); and at least three of P7, P8, P9, P10, PI 1, PI 2 are Arg with the rest being any amino acid or absent.
[0042] In yet an additional embodiment, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6 (SEQ ID NO:39) or P6, P5, P4, P3, P2, PI (SEQ ID NO.40). PI is Cha, or Nal(2); P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F) or (Phe-4CF3); P3 is Ser; P4 is Τφ; P5 is Ser; and P6 is Bpa, or (Ser-Tyr).
[0043] In yet a further embodiment, a peptide or peptidomimetic sequence comprising the following structure:Pl, P2, P3, P4, P5, P6 (SEQ ID NO:41); P6, P5, P4, P3, P2, PI (SEQ ID NO:42); PI, P2, P3, P4, P5, P6, P7, P8, P9, PIO, PI 1, P12 (SEQ ID NO:43); PI, P2, P3, P4, P5, P6, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:44); P6, P5, P4, P3, P2, PI, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:45); P6, P5, P4, P3, P2, PI, P12, PI 1, P10, P9, P8, P7 (SEQ ID NO:46); P7, P8, P9,
PI O, PI 1, P12, PI, P2, P3, P4, P5, P6 (SEQ ID NO:47); P7, P8, P9, PIO, PI 1, P12, P6, P5, P4, P3, P2, PI (SEQ ID NO:48); P12, PI 1, PIO, P9, P8, P7, PI, P2, P3, P4, P5, P6 (SEQ ID NO:49); P12, PI 1, PIO, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:50); P12, PI 1, P6, P9, P8, P7, P2, PI (SEQ ID N0:51); P12, PI 1 , PIO, P6, P9, P4, P7, P2, PI (SEQ ID NO:52); PI, P2, P7, P8, P9, P6, PI 1, P12 (SEQ ID NO:53); or PI, P2, P7, P4, P9, P6, PIO, PI 1, P12 (SEQ ID NO:54). PI is Cha, or Nal(2); P2 is (Phe-2,3,4,5,6-F), (Phe-3,4,5F) or (Phe-4CF3); P3 is any amino acid (e.g., Ser, or Pro); P4 is d- or 1-Trp; P5 is any amino acid (e.g., Ser, or Pro); P6 is Bpa or (Ser-Tyr); P7 is Arg; P8 is Arg; P9 is Arg; PIO is Gin or Arg; PI 1 is Arg; and PI 2 is d- or 1-Arg.
[0044] In still further embodiments, a peptide or peptidomimetic sequence includes the following structure: PI, P2, P3, P4, P5, P6, P7, P8, P9, P10, PI 1, P12 (SEQ ID NO:55); P12, PI 1, PIO, P9, P8, P7, P6, P5, P4, P3, P2, PI (SEQ ID NO:56); P12, PI 1, PIO, P6, P9, P4, P7, P2, PI (SEQ ID NO:57); or PI, P2, P7, P4, P9, P6, PIO, PI 1, P12 (SEQ ID NO:58). PI is Cha or Nal(2); P2 is (Phe-2,3,4,5,6-F); P3 is Ser; P4 is Trp; P5 is Ser; P6 is Bpa or (Ser-Tyr); P7 is Arg; P8 is Arg; P9 is Arg; PIO is Gin or Arg; PI 1 is Arg; and PI 2 is Arg.
[0045] In particular aspects, a peptide or peptidomimetic sequence includes the following structure: (d-Bpa) (d-Ser)(d-Trp)(d-Ser) (d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg) (d-Arg) (d-Arg) (d- Gln)(d-Arg) (d-Arg) (CBP501; SEQ ID NO:80); (d-Arg) (d-Arg) (d-Arg) (d-Gln)(d-Arg) (d-Arg) (d-Bpa)(d-Ser)(d-Trp)(d-Ser) (d-Phe-2,3,4,5,6-F) (d-Cha) (SEQ ID NO:100); (d-Bpa) (d-Ser)(d- Τφ)^-86Γ) (d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg) (d-Arg) (d-Gln) (d-Arg) (d-Arg) (d-Arg) (SEQ ID NO:59); (d-Arg) (d-Arg) (d-Gln) (d-Arg) (d-Arg) (d-Arg) (d-Bpa) (d-Ser)(d-Trp)(d-Ser) (d-Phe- 2,3,4,5,6-F) (d-Cha) (SEQ ID NO:60); (d-Cha) (d-Phe-2,3,4,5,6-F)(d-Ser)(d^) (d-Ser) (d-Bpa) (d-Arg) (d-Arg) (d-Arg) (d-Gln)(d-Arg) (d-Arg) (SEQ ID NO:61); (d-Arg) (d-Arg) (d-Arg) (d- Gln)(d-Arg) (d-Arg) (d-Cha) (d-Phe-2,3,4,5,6-F)(d-Ser) (d^)(d-Ser)(d-Bpa)(SEQ ID NO:62); (d-Cha)(d-Phe-2,3,4,5,6-F) (d-Ser)(d-T ) (d-Ser) (d-Bpa) (d-Arg) (d-Arg) (d-Gln) (d-Arg) (d- Arg) (d-Arg) (SEQ ID NO:63); (d-Arg) (d-Arg) (d-Gln) (d-Arg) (d-Arg) (d-Arg) (d-Cha) (d-Phe- 2,3,4,5,6-F) (d-Ser)(d-Trp) (d-Ser) (d-Bpa) (SEQ ID NO:64); (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d- Arg) (d-Arg) (d-Cha) (d-Phe-2,3,4,5,6-F) (d-Ser) (d-Trp)(d-Ser) (d-Bpa) (SEQ ID NO:65); (d- Cha) (d-Phe-2,3,4,5,6-F) (d-Ser)(d-Tφ)(d-Ser) (d-Bpa) (d-Arg)(d-Arg) (d-Arg)(d-Arg) (d-Arg) (d-Arg) (SEQ ID NO:66); (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Bpa) (d-Ser)(d- Τφ)^-8ε (d-Phe-2,3,4,5,6-F)(d-Cha) (SEQ ID NO:67); (d-Bpa) (d-Ser) (d^)(d-Ser) (d-Phe- 2,3,4,5,6-F)(d-Cha) (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Arg)(SEQ ID NO:68); (d- Arg)(d-Arg)(d-Bpa)(d-Arg)(d-Arg)(d-Arg) (d-Phe-2,3,4,5,6-F) (d-Cha) (SEQ ID NO:69); (d-Cha) (d-Phe-2,3,4,5,6-F) (d-Arg) (d-Arg) (d-Arg) (d-Bpa) (d-Arg)(d-Arg) (SEQ ID NO:70); (d-Arg) (d-Arg) (d-Arg) (d-Bpa) (d-ArgXd-Τφ) (d-Arg) (d-Phe-2,3,4,5,6-F)(d-Cha) (SEQ ID NO:71); (d-
Cha) (d-Phe-2,3 ,4,5,6-F) (d-Arg)(d-Trp) (d-Arg) (d-Bpa) (d-Arg) (d-Arg) (d-Arg) (SEQ ID NO-.72); (d-Arg) (d-Arg) (d-Arg) (d-Arg) (d-Bpa) (d-ArgXd-Τφ) (d-Arg) (d-Phe-2,3,4,5,6-F)(d- Cha) (SEQ ID NO:73); (d-Cha) (d-Phe-2,3,4,5,6-F) (d-Arg)(d-Trp) (d-Arg) (d-Bpa) (d-Arg) (d- Arg) (d-Arg) (d-Arg) (SEQ ID NO:74); (d-Arg) (d-Arg) (d-Arg)(d-Bpa)(d-Arg)(d-Arg) (d-Arg) (d-Phe-2,3,4,5,6-F)(d-Cha) (SEQ ID NO.75); or (d-Cha) (d-Phe-2,3,4,5,6-F) (d-Arg) (d-Arg) (d- Arg) (d-Bpa) (d-Arg) (d-Arg) (d-Arg) (SEQ ID NO:76); (d-Bpa)(d-Ser)(d-Trp)(d-Ser)(d-Phe- 2,3,4,5,6-F) (d-Cha)(d-Arg) (d-Arg)(d-Arg)(d-Gln)(d-Arg)(d-Arg) (SEQ ID NO:77).
[0046] In some embodiments, there are provided physiologically acceptable salts of CBP501 (SEQ ID NO:80), for example, a salt of an inorganic base, a salt of an organic base, a salt of an inorganic acid, a salt of an organic acid, a salt of a basic or acidic amino acid and the like. Such salts can be produced by a method known methods (e.g., acetate salt can be produced by a step of liquid chromatography using acetate-containing solvent).
[0047] Examples of salts with inorganic base include alkali metal salt such as sodium salt, potassium salt and the like, alkaline earth metal salt such as calcium salt, magnesium salt and the like, and aluminum salt, ammonium salt and the like.
[0048] Examples of salts with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine,
trometham i ne[tris(hydroxymethy l)am inomethane] , tert-buty lam i e, cyclohexy lam ine, benzylamine, dicyclohexylamine, Ν,Ν'-dibenzylethylenediamine and the like.
[0049] Examples of salts with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
[0050] Examples of salts with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
[0051] Examples of salts with basic amino acid include salts with arginine, lysine, ornithine and the like.
[0052] Examples of salts with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
[0053] In some embodiments, there are provided salts of an organic acid such as acetic acid and the like. The number of acetic acid attached to a peptide or peptidomimetic as set forth herein (e.g., CBP501), in particular, can vary, including, for example 4 or 5 acetic acids per a peptide or peptidomimetic as set forth herein (e.g., CBP501). Alternatively, a mixture of a peptide or
peptidomimetic (e.g., CBP501) acetate salts having different number of acetic acids attached thereto (for example, mixture of 4 acetate and 5 acetate etc.) may be used.
[0054] In some embodiments, there is provided an acetate salt of a peptide compound CBP501: (d-Bpa)(d-Ser)(d-T )(d-Ser)(d-Phe-2,3,4,5,6-F)(d-Cha)(d-Arg)(d-Arg)(d-Arg)(d-Gln)(d-Arg)(d- Arg) (SEQ ID NO:80). A method of producing an acetate salt of a peptide compound shown by SEQ ID No:80 may comprise a step of performing liquid chromatography using an acetate- containing solvent.
[0055] In additional aspects, peptides and peptidomimetic sequences include one or more 1-type or d-type residues; a d-residue substituted with a 1 -residue; or a 1 -residue substituted with a d- residue.
[0056] Peptides and peptidomimetic sequences include one or more of the following activities: inhibits proliferation of a cell; abrogates cell cycle G2 checkpoint of a cell; stimulates apoptosis of a cell; stimulates catastrophe of a cell.
[0057] Peptides and peptidomimetic sequences include a sequence having a length from about 6 to about 12, 10 to about 20, 18 to about 25, 25 to about 100, 25 to about 200, or 50 to about 300 residues in length.
[0058] Further provided are compositions including the peptides and peptidomimetic sequences disclosed herein. In one embodiment, a composition includes a peptide or peptidomimetic sequence and a nucleic acid damaging agent. In another embodiment, a composition includes a peptide or peptidomimetic sequence and an anti -proliferative agent. In an additional embodiment, a composition includes a pharmaceutically acceptable carrier or excipient and a peptide or peptidomimetic sequence and optionally a nucleic acid damaging agent or an anti-proliferative agent.
[0059] In some embodiments, methods include administering a nucleic acid damaging agent, a nucleic acid damaging treatment, an anti-proliferative agent, or an anti-proliferative treatment to the subject. In particular aspects, the agent or treatment comprises a drug (e.g., a
chemotherapeutic drug such as 5-fluorouracil (5-FU), rebeccamycin, adriamycin (ADR), bleomycin (Bleo), pepleomycin, a cisplatin derivative such as cisplatin (CDDP) carboplatin, picoplatin, nedaplatin, miriplatin, satraplatin, triplatin, lipoplatin, mitaplatin, oxaliplatin, or camptotecin (CPT)), radiation (e.g., UV radiation, IR radiation, or alpha-, beta- or gamma- radiation), a radioisotope (e.g., 1131, 1125, 90Y, 177Lu, 213Bi, or 21 lAt), environmental shock (e.g., hyperthermia).
[0060] As used herein, the terms "peptide," "polypeptide" and "protein" are used
interchangeably and refer to two or more amino acids covalently linked by an amide bond or non-
amide equivalent. The peptides can be of any length. For example, the peptides can have from about 5 to 100 or more residues, such as, 5 to 12, 12 to 15, 15 to 18, 18 to 25, 25 to 50, 50 to 75, 75 to 100, or more in length. The peptides may include 1- and d-isomers, and combinations of 1- and d-isomers. The peptides can include modifications typically associated with post-translational processing of proteins, for example, cyclization (e.g., disulfide or amide bond), phosphorylation, glycosylation, carboxylation, ubiquitination, myristylation, or lipidation.
[0061] Peptides disclosed herein further include compounds having amino acid structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues, so long as the mimetic has one or more functions or activities. The compounds disclosed herein therefore include "mimetic" and "peptidomimetic" forms.
[0062] As used herein, the terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics of the peptides. The mimetic can be entirely composed of synthetic, non-natural amino acid analogues, or can be a chimeric molecule including one or more natural peptide amino acids and one or more non-natural amino acid analogs. The mimetic can also incorporate any number of natural amino acid conservative substitutions as long as such substitutions do not destroy the mimetic's activity. As with polypeptides which are conservative variants, routine testing can be used to determine whether a mimetic has the requisite activity, e.g., that it has detectable cell cycle G2 checkpoint abrogating activity. A mimetic, when administered to a subject or contacted on a cell, that detectably disrupts the G2 cell cycle checkpoint, would therefore have G2 checkpoint abrogating activity.
[0063] Peptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. For example, a polypeptide can be characterized as a mimetic when one or more of the residues are joined by chemical means other than an amide bond. Individual peptidomimetic residues can be joined by amide bonds, non-natural and non- amide chemical bonds other chemical bonds or coupling means including, for example, glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, Ν,Ν'- dicyclohexylcarbodiimide (DCC) or Ν,Ν'-diisopropylcarbodiimide (DIC). Linking groups alternative to the amide bond include, for example, ketomethylene (e.g.,— C(= )— CH2— for — C(=0)— NH— ), aminomethylene (CH2— NH), ethylene, olefin (CH=€H), ether (CH2— O),
thioether (CH2— S), tetrazole (CN— ), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide and Backbone Modifications," Marcel Decker, N.Y.).
[0064] As discussed, a peptide can be characterized as a mimetic by containing one or more non- natural residues in place of a naturally occurring amino acid residue. Non-natural residues are known in the art. Particular non-limiting examples of non-natural residues useful as mimetics of natural amino acid residues are mimetics of aromatic amino acids include, for example, D- or L- naphylalanine; D- or L-phenylglycine; D- or L-2 thieneylalanine; D- or L-l, -2,3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)- alanine; D- or L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)-phenylglycine; D-(trifluoromethyl)- phenylglycine; D-(trifluoromethyl)-phenylalanine; D-p-fluoro-phenylalanine; D- or L-p- biphenylphenylalanine; K- or L-p-methoxy-biphenylphenylalanine; D- or L-2- indole(alkyl)alanines; and D- or L-alkylainines, where alkyl can be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a non- acidic amino acid. Aromatic rings of a non-natural amino acid that can be used in place of a natural aromatic rings include, for example, thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.
[0065] Mimetics of acidic amino acids can be generated by substitution with non-carboxylate amino acids while maintaining a negative charge; (phosphono) alanine; and sulfated threonine. Carboxyl side groups (e.g., aspartyl or glutamyl) can also be selectively modified by reaction with carbodiimides (R'— N— C— N— R') including, for example, l-cyclohexyl-3(2-morpholinyl- (4-ethyl) carbodiimide or l-ethyl-3(4-azonia-4,4-dimetholpentyl) carbodiimide. Aspartyl or glutamyl groups can also be converted to asparaginyl and glutaminyl groups by reaction with ammonium ions.
[0066] Mimetics of basic amino acids can be generated by substitution, for example, in addition to lysine and arginine, with the amino acids ornithine, citrulline, or (guanidino)-acetic acid, or (guanidino)alkyl-acetic acid, where alkyl can be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a non-acidic amino acid. Nitrile derivative (e.g., containing the CN-moiety in place of COOH) can be substituted for asparagine or glutamine. Asparaginyl and glutaminyl residues can be deaminated to the corresponding aspartyl or glutamyl residues.
[0067] Arginine mimetics can be generated by reacting arginyl with one or more reagents including, for example, phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, or ninhydrin, optionally under alkaline conditions. Tyrosine residue mimetics can be generated by reacting
tyrosyl with aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitrom ethane can be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
[0068] Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysinyl with succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino- containing residue mimetics can also be generated by reaction with imidoesters, such as methyl picohnimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid,
O-methytisourea, 2,4, pentanedione, and transamidase-catalyzed reactions with glyoxylate.
[0069] Methionine mimetics can be generated by reaction with methionine sulfoxide. Proline mimetics of include, for example, pipecolic acid, thiazolidine carboxylic acid, 3- or 4-hydroxy proline, dehydroproline, 3- or 4-methylproline, and 3,3,-dimethylproline. Histidine mimetics can be generated by reacting histidyl with diethylprocarbonate or para-bromophenacyl bromide.
Other mimetics include, for example, those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha- amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine; methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C- terminal carboxyl groups.
[0070] One or more residues can also be replaced by an amino acid (or peptidomimetic residue) of the opposite chirality. Thus, any amino acid naturally occurring in the L-configuration (which can also be referred to as R or S, depending upon the structure of the chemical entity) can be replaced with the same amino acid or a mimetic, but of the opposite chirality, referred to as the D- amino acid, but which can additionally be referred to as the R- or S-form.
[0071] Peptides and peptidomimetics further include modified forms of the sequences set forth herein, provided that the modified form retains, at least a part of, the function of the unmodified or reference peptide or peptidomimetic. For example, a modified peptide or peptidomimetic will retain at least a part of cell proliferative inhibiting or G2 abrogating activity, but may have increased or decreased cell proliferative inhibiting or G2 abrogating activity relative to reference peptide or peptidomimetic.
[0072] Modified peptides and peptidomimetics can have one or more amino acid residues substituted with another residue, added to the sequence or deleted from the sequence. In one embodiment, the modified peptide or peptidomimetic has one or more amino acid substitutions, additions or deletions (e.g., 1-3,3-5, 5-10 or more). In one aspect, the substitution is with an amino acid or mimetic whose side chain occupies a similar space with the reference amino acid or mimetic (the amino acid or mimetic that is being substituted). In still another aspect, the
substitution is with a non-human amino acid which is structurally similar to the human residue. In a particular aspect, the substitution is a conservative amino acid substitution.
[0073] As used herein, the term "similar space" means a chemical moiety that occupies a three- dimensional space similar in size to a reference moiety. Typically, a moiety that occupies a similar space will be similar in size to the reference moiety. An amino acid or mimetic that "occupies a similar side chain space" has a side chain that occupies a three-dimensional space similar in size to the reference amino acid or mimetic. Specific examples for d-(Phe-2,3,4,5,6-F), l-(Phe-2,3 ,4,5,6-F), d-(Phe-3,4,5F), l-(Phe-3,4,5F), d-(Phe-4CF3) or l-(Phe-4CF3), are (1 or d-Phe- 2R1,3R2,4R3,5R4,6R5) where R1,R2,R3,R4,R5 can be chloride, bromide, fluoride, iodide, hydrogen, hydrogen oxide or absent. For small molecules, e.g., fluoride which has a size of about 1 Angstrom, similar space may be absence of a moiety.
[0074] The term "conservative substitution" means the replacement of one amino acid by a biologically, chemically or structurally similar residue. Biologically similar means that the substitution is compatible with biological activity, e.g., anti-cell proliferative or G2 abrogating activity. Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or having similar size. Chemical similarity means that the residues have the same charge or are both hydrophilic or hydrophobic. Particular examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, and the like.
[0075] Peptides and peptidomimetics therefore include peptides and peptidomimetics having a sequence that is not identical to a sequence of peptides and peptidomimetics sequences set forth in Table 1. In one embodiment, a peptide or peptidomimetic has a sequence having 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more identity with a sequence set forth in Table 1. In one aspect, the identity is over a defined area of the sequence, e.g., the amino or carboxy terminal 3-5 residues.
[0076] The peptides and peptidomimetics can be produced and isolated using any method known in the art. Peptides can be synthesized, whole or in part, using chemical methods known in the art (see, e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; and Banga, A. K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, Pa.). Peptide synthesis can be performed using various solid-phase techniques (see, e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may
be achieved, e.g., using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the manufacturer's instructions.
[0077] Individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies known in the art (see, e.g., Organic Syntheses Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons, Inc., NY). Peptides and peptide mimetics can also be synthesized using combinatorial methodologies. Techniques for generating peptide and peptidomimetic libraries are well known, and include, for example, multipin, tea bag, and split-couple-mix techniques (ses, for example, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1 :114-119; Ostergaard (1997) Mol. Divers. 3: 17-27; and Ostresh(1996) Methods Enzymol. 267:220-234). Modified peptides can be further produced by chemical modification methods (see, for example, Belousov (1997) Nucleic Acids Res. 25:3440- 3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; and Blommers (1994) Biochemistry 33:7886-7896).
[0078] Peptides can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, or to identify and isolate antibodies or antibody- expressing B cells. Domains facilitating detection and purification include, for example, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals; protein A domains that allow purification on immobilized immunoglobulin; and the domain utilized in the FLAGS™ extension/affinity purification system (Immunex Corp, Seattle, Wash.) The inclusion of a cleavable linker sequence such as Factor Xa or enterokinase (Invitrogen, San Diego Calif.) between a purification domain and the peptide can be used to facilitate peptide purification. For example, an expression vector can include a peptide- encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34: 1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-14). The histidine residues facilitate detection and purification of the fusion prtein while the enterokinase cleavage site provides a means for purifying the peptide from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins is known in the art (see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53).
[0079] In some embodiments there are provided nucleic acids encoding the peptides disclosed herein. In particular embodiments, a nucleic acid encodes peptide sequences herein having a length of about 8 to 12, 12 to 15, 15 to 18, 15 to 20, 18 to 25, 20 to 25, 25 to 35, 25 to 50 or 50 to 100 amino acids or more in length.
[0080] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to all forms of nucleic acid, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The nucleic acids can be double, single strand, or triplex, linear or circular Nucleic acids include genomic DNA, cDNA, and antisense. RNA nucleic acid can be spliced or unspliced mRNA, rRNA, tRNA or antisense (e.g., RNAi). Nucleic acids include naturally occurring, synthetic, as well as nucleotide analogues and derivatives. Such altered or modified polynucleotides include analogues that provide nuclease resistance, for example. Nucleic acid lengths also can be less than the exemplified peptide sequences. For example, a subsequence of any of the peptide sequences can encode a peptide having anti-proliferative or G2 abrogating activity.
[0081] Nucleic acid can be produced using any of a variety of well known standard cloning and chemical synthesis methods and can be altered intentionally by site-directed mutagenesis or other recombinant techniques known to those skilled in the art. Purity of polynucleotides can be determined through sequencing, gel electrophoresis and the like.
[0082] Nucleic acids may be inserted into a nucleic acid construct in which expression of the nucleic acid is influenced or regulated by an "expression control element," the combination referred to as an "expression cassette." The term "expression control element" means one or more sequence elements that regulates or influences expression of a nucleic acid sequence to which it is operatively linked. An expression control element operatively linked to a nucleic acid sequence controls transcription and, as appropriate, translation of the nucleic acid sequence.
[0083] The term "operatively linked" refers to a functional juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. Typically expression control elements are juxtaposed at the 5' or at the 3' ends of the gene but can also be intronic. Promoters are generally positioned 5' of the coding sequence. A "promoter" is meant a minimal sequence element sufficient to direct transcription.
[0084] Expression control elements include promoters, enhancers, transcription terminators, gene silencers, a start codon (e.g., ATG) in front of a protein-encoding gene. Expression control elements activate constitutive transcription, inducible transcription (i.e., require an external signal for activation), or derepress transcription (i.e., a signal turns transcription off; removing the signal activates transcription). Expression cassettes can also include control elements sufficient to render gene expression controllable for specific cell-types or tissues (i.e., tissue-specific control elements).
[0085] Nucleic acids may be inserted into a plasmid for propagation into a host cell and for subsequent genetic manipulation. A plasmid is a nucleic acid that can be stably propagated in a host cell; plasmids optionally contain expression control elements in order to drive expression of
the nucleic acid encoding peptide in the host cell. The term "vector" is used herein synonymously with a plasmid and may also include an expression control element for expression in a host cell. Plasmids and vectors generally contain at least an origin of replication for propagation in a cell and a promoter. Plasmids and vectors are therefore useful for genetic manipulation of peptide encoding nucleic acids, for producing peptides, and for expressing the peptides in host cells or whole organisms, for example.
[0086] Peptides may therefore be expressed in bacterial systems using constitutive promoters such as T7, or inducible promoters such as pL of bacteriophage π, plac, ptrp, ptac (ptrp-lac hybrid promoter); in yeast systems using constitutive promoters such as ADH or LEU2 or an inducible promoter such as GAL (see, e.g., Ausubel et al., In: Current Protocols in Molecular Biology, Vol. 2, Ch. 13, ed., Greene Publish. Assoc. & Wiley Interscience, 1988; Grant et al. Methods in Enzymology, 153:516 (1987), eds. Wu & Grossman; Bitter Methods in Enzymology, 152:673 (1987), eds. Berger & Kimmel, Acad. Press, N.Y.; and, Strathern et al., The Molecular Biology of the Yeast Saccharomyces (1982) eds. Cold Spring Harbor Press, Vols. I and II; R. Rothstein In: DNA Cloning, A Practical Approach, Vol. 1 1, Ch. 3, ed. D. M. Glover, TRL Press, Wash., D. C, 1986); in insect cell systems using constitutive or inducible promoters such as ecdysone; and in mammalian cell systems using constitutive promoters such as SV40, RSV, or inducible promoters derived from the genome of mammalian cells such as metallothionein IIA promoter, heat shock promoter, or derived from mammalian virus such as adenovirus late promoter or the inducible mouse mammary tumor virus long terminal repeat. Peptide expression systems further include vectors designed for in vivo use including adenoviral vectors (U.S. Pat. Nos. 5,700,470 and 5,731 , 172), adeno-associated vectors (U.S. Pat. No. 5,604,090), herpes simplex virus vectors (U.S. Pat. No. 5,501 ,979) and retroviral vectors (U.S. Pat. Nos. 5,624,820, 5,693,508 and
5,674,703 and WIPO publications WO92/05266 and W092/14829). Bovine papilloma virus (BPV) has also been employed in gene therapy (U.S. Pat. No. 5,719,054). Such gene therapy vectors also include CMV based vectors (U.S. Pat. No. 5,561,063).
EXAMPLES
[0087] CBP501 (SEQ ID NO:80) is an anti-cancer drug candidate that was investigated in two randomized Phase II clinical trials for patients with non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). CBP501 has been shown to have two mechanisms of action, namely calmodulin modulation and G2 checkpoint abrogation. A biomarker to predict sensitivity to CBP501 is disclosed herein. Twenty-eight NSCLC cell lines were classified into two subgroups, CBP501 sensitive and insensitive, by
quantitatively analyzing the cis-diamminedichloro-platinum (II) (CDDP)-enhancing activity of CBP501 through treatments with short term (1 hour) co-exposure to CDDP and CBP501 or to either alone. Microarray analysis was performed on these cell lines to identify gene expression patterns that correlated with CBP501 sensitivity. It was found that multiple Nuclear factor erythroid-2 related factor2 (Nrf2) target genes showed high expression in CBP501 -insensitive cell lines. Western blot and imunnocytochemical analysis for Nrf2 in NSCLC cell lines also indicated higher protein level in CBP501 insensitive cell lines.
Moreover, CBP501 sensitivity is modulated by silencing or Sulforaphane (SFN) induced over-expression of Nrf2. These results indicate that Nrf2 transcriptional factor is a potential candidate as a biomarker for resistance to CBP501. This Example identifies those
subpopulations of patients who would respond well to the CBP501 and CDDP combination treatment for NSCLC.
[0088] Establishing quantifiable markers that predict sensitivity to a particular drug is an aim of personalized medicine. Several anti-cancer drugs have been developed based on known oncogenic mutations and the presence of the mutation by itself has been found to be a useful biomarker for these drugs. Examples include some tyrosine kinase inhibitors, including gefitinib and erlotinib, that target epidermal growth factor receptor (EGFR) in NSCLC and for which efficacy depends on the presence of particular EGFR mutations (1, 2); Crizotinib, which is highly effective when NSCLC cells harbor the EML4-ALK fusion gene (3); and the BRAF inhibitor Vemurafenib, which is highly effective when melanoma cells carry the V600E mutation of BRAF (4).
[0089] It has been indicated that a combination of CDDP plus CBP501 showed evidence of clinical activity in patients with platinum-resistant ovarian carcinoma and MPM (5). The primary endpoint for efficacy was achieved on MPM (6). G2 checkpoint-abrogation had been proposed as a mechanism of action (MO A) based on the observation that CBP501 (i) inhibits multiple kinases that phosphorylate CDC25C at Ser216, (ii) binds directly to 14-3-3 protein, which forms suppressive complexes with phospho-CDC25C, (iii) attenuates phosphorylation of CDC25C at Ser216 and (iv) reduces the accumulation of cancer cells at G2/M upon lengthy combined exposure with CDDP or bleomycin (BLM ) (7, 8).
[0090] An additional MOA for CBP501was demonstrated. This entails direct interaction of CBP501 with calmodulin, which leads to increased uptake of CDDP into cancer cells upon much shorter exposure to and at lower doses of CBP501 than the conditions required for G2 checkpoint abrogation (9). CDDP uptake is known to depend on multiple transporters and
channels (10). Calmodulin-CBP501 interaction might affect a multiple transporter to increase CDDP uptake into cancer cells.
[0091] Nrf2 is a transcription factor that regulates the expression of many antioxidant genes, including those related to glutathione synthesis (1 1). In tumorigenesis, expression of particular oncogenic alleles of Kras, BRAF and Myc increases the levels of intracellular antioxidants by inducing Nrf2 expression ( 12). Nrf2 also regulates the expression of genes related to drug detoxification and transport (13).
[0092] This Example focuses on CBP501 's effect on promoting CDDP uptake rather than G2 checkpoint abrogation by examining cells only upon short-term exposure to CBP501 and CDDP. Twenty-eight NSCLC cell lines were quantitatively defined as sensitive or insensitive to CBP501 by analyzing their response to a short (lh) co-exposure with CDDP and CBP501 as compared with either drug alorte. Comprehensive gene expression analysis (microarray) was performed on these cell lines to identify the sensitivity markers for this MOA of CBP501. Multiple genes regulated by the Nrf2 transcription factor were identified as having high expression in CBP501 insensitive cell lines. Additionally, knock-down of Nrf2 by using Nrf2 sh-RNA revealed that Nrf2 expression is required for resistance to CBP501.
[0093] Materials and Methods
[0094] Cell culture and reagents. Human NSCLC cell lines were cultured in a variety of media, each supplemented with 10% fetal bovine serum (Invitrogen, San Diego, CA) at 37 °C with 5% C02/air. The media used was RPMI1640 (Sigma-Aldrich, St. Louis, MO) for NCI- H1755, NCI-H2030, NCI-H1437, NCI-H2122, NCI-H2172, NCI-H2228, NCI-H1563, NCI- HI 944, NCI-H1993, NCI-H1734, NCI-H1568, NCI-H2444, NCI-H2291, NCI-H2347, NCI- H1838, NCI-HI 299, HCC827, NCI-H1975, NCI-H1 155, NCI-H522 and NCI-H1703;
RPMI1640 supplemented with 2mM L-glutamine (Invitrogen) for NCI-H727; RPMI1640 supplemented with 4.5 g/L D-glucose (Sigma-Aldrich), lOmM HEPES (Sigma-Aldrich) and ImM sodium pyruvate (Sigma-Aldrich) for NCI-H358, NCI-H520, NCI-H23, NCI-H647 and NCI-H838; Ham's F12K (Sigma-Aldrich) for A549. CDDP was purchased from Sigma- Aldrich. Sulforaphane (SFN) was purchased from Sigma-Aldrich. All NSCLC cell lines were purchased from ATCC and STR analysis had been performed by ATCC to authenticate the identity of each cell line. All cell lines were used within three months after thawing.
[0095] Cell cycle analysis. Cells were plated in 24-well plates and incubated for 24 hours. The cells were treated with or without CDDP plus or minus CBP501 at the indicated concentration for the indicated times. The cells were harvested and stained with Krishan's solution (0.1% sodium citrate, 50 μg/ml propidium iodide, 20 μg/ml RNase A, 0.5% NP-40).
Stained cells were analyzed by FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) using CELLQuest software (Becton Dickinson).
[0096] Antibodies. Antibodies were purchased from the indicated sources: anti-NROB l, anti- Grx, anti-Prx, anti-yGCSc, anti-yGCSm and anti-Gpxl (SantaCruz, Dallas, TX); anti-MLC, anti-G6PD, anti-ABCC2, anti-KEAPl, anti-BACHl, anti-Trxl, anti-SODl, anti-HOl, anti- NQOl, anti-IQGAP l and anti-ATM (Cell Signaling Technology, Beverly, MA); anti-GSR, anti-A RIC I, anti-AKRlC3, anti-AKRIB lO and anti-Nrf2 (Epitomics, San Francisco, CA).
[0097] Microarray and Gene Expression Analysis. NSCLC cell lines were grown in a monolayer prior to RNA isolation. Total RNA was isolated using RNeasy Mini Kit (Qiagen, Tokyo, Japan). Agilent Expression Array analysis of the isolated total RNA samples was performed at TAKARABIO Inc. (Shiga, Japan). Each analysis of total RNA of a cell line was performed in triplicate. Preliminary statistical treatment (One-way ANOVA and Benjamini- Hochberg method: False Discovery Rate < 0.05) of the gene expression data was performed by TAKARABIO Inc.
[0098] Lentivirus infection. Nrf2 shRNA lentivirus particles and Control shRNA lentivirus particles were purchased from SantaCruz. Lentivirus infection was performed according to manufacturer's instructions. Cells (50% confluence) were treated with 5μg/ml Polybrene (SantaCruz) prior to virus infection. One day after addition of virus, the cells were transferred to fresh medium and cells were selected by treatment with Puromycin (SantaCruz).
[0099] Immunofluorescence. Cells growing on coverslips were fixed with 4 % paraformaldehyde (15 min), washed with phosphate-buffered saline (PBS) (five minutes, three times) and then blocked in 1 χ PBS with 1 % Block Ace (DS pharma, Osaka, Japan). They were then incubated with antibodies using standard protocols. Primary antibodies included anti-Nrf2 (1 : 100), anti- AKR1 C1(1 : 100), anti-AKRl C3(l : 100) and anti-AKRIBlO (1 : 100). Secondary antibodies were labeled with Alexa-488 (Invitrogen) and Hoechst 33342 (DOJINDO, Kumamoto, Japan) was used to stain DNA. Confocal microscopy was performed using FVlOi confocal microscope (OLYMPUS, Tokyo, Japan).
[00100] Western blot analysis. Cells (50% confluence) were treated with or without SFN at indicated concentrations for the indicated times. The cells were harvested and lysed (30 min on ice) in lysis buffer [50 raM Tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), 100 mM NaCl, 0.5% NP- 40, 2 mM DTT, 50 mM NaF, 1 mM Na3V04, 1 μΜ microcystin, proteinase inhibitors cocktail (Roche, Mannheim, Germany)]. The lysates were clarified by centrifugation (20600g, 4°C), and the supematants were assayed for protein content using the detergent-compatible protein assay kit (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. The whole cell lysates (60
μg) were run on 10-12% SDS-PAGE. Protein from each gel was transferred onto a polyvinylidene difluoride, (PVDF), membrane (Bio-Rad). The membrane was blocked at room temperature for 1 h in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl and 0.05% Tween-20) containing 1 % Block Ace (DS pharma) and incubated with primary antibody overnight at 4 °C. The membrane was incubated further with anti-peroxtdase conjugated secondary antibody (Cell Signaling) for one hour at room temperature after washing, and the signals were detected using the enhanced chemiluminescence detection system (ECL Advance Western Blotting Detection Kit, GE Healthcare). Detected bands were quantified using Lumino-mater LAS-4000 instrument (Fujifilm, Tokyo, Japan).
Mutation search for NSCLC cell lines. Searching for Keapl mutations in NSCLC cell lines was performed using the on-line database, Catalogue of somatic mutations in cancer (COSMIC) (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).
[0101] Results
[0102] NSCLC cell lines and the sensitivity to CBP501
[0103] CBP501 sensitizes tumor cells to CDDP, as shown by various methods including colony formation assays, in vitro viability assays, and flow-cytometry analysis, which measures systematic changes in cell cycle distribution. The results between the different methods correlate well (8, 9) and differential sensitivity to CBP501 varies consistently for different cell lines (9).
[0104] Here, the change in the cell cycle distribution, as indicated by flow-cytometry, was used to estimate the sensitivity of NSCLC cell lines to CBP501 -enhanced cytotoxicity to CDDP. Such changes were monitored in cells treated with CDDP in the presence or absence of CBP501. The utility of this analysis for assessing the effectiveness of anti-cancer therapy is based on the absence of functioning Gl/S checkpoint regulation in the cell cycle of many types of cancer cells ( 14). Lack of a functional Gl/S checkpoint leads to an accumulation of cancer cells in G2/M phase upon their exposure to DNA-darhaging anticancer agents (14, 15).
[0105] To assess the CDDP-enhancing activity of CBP501, one can examine either of two dose-response curves in which the X-axis indicates the dose of CDDP and Y-axis indicates either the number of cells in subGl or in G2/M. The transition and peak in either dose- response curve will shift to the left in the presence of CBP501 for CBP501 -sensitive cells, indicating the enhanced ability of CDDP to change the cell cycle distribution. By such an analysis of NCI-H1703 cells, the presence of CBP501 resulted in an approximate eight-fold increase in effectiveness of CDDP to alter the cell cycle distribution (Fig.lA-D). On the other
hand, the NCI-H 1437 cell line did not exhibit any detectable shift in the dose-response curve of CDDP caused by CBP501 (Fig.lE-H). Using this criterion based on CBP501 's ability to shift the CDDP-induced subGl or G2/M dose-response curve, twelve NSCLC cell lines were classified as being either, CBP501-sensitive or CBP501-insensitive. Cell lines that shifted the curve two fold or more were classified as CBP501 sensitive cells and those that shifted the curve less than two fold were classified as CBP501 insensitive (Table 1). Classification of CBP501 sensitivity in NSCLC cell lines.
Table 1
;¾« S f Cgo.501
NCI-H2030 1
NO-HI 437 1
NCI-H2122 t
N CI-H2172 1.5
'•iC'-H2223 1.5
:NCI-H154* 1.5
N CI-H 1 S6S 2
NC1-H2444 2
N CI-H22&1 2
NCI-H2347 4
N:CI-H.1S58; 4
NCI-H1703 S
[0106] Comprehensive gene expression analysis indicates that some Nrf2 target genes might have up-regulated expression in CBP501 -insensitive cell lines
[0107] Comprehensive gene expression (Microarray) analysis was performed on the twelve NSCLC cell lines listed in Table 1. Upon setting the threshold signal value for the expression level to be 5000, forty genes showed more than seventy percent of correlation with CBP501 sensitivity (Fig.2A). These identified genes were subdivided into two categories: genes highly expressed in sensitive cell lines or genes highly expressed insensitive cell lines.
Examination of the average expression level values for groupings of genes individually classified as sensitive or insensitive indicated that some groupings of insensitive genes consistently exhibited discernable differences in expression level when CBP501 sensitive and insensitive cell lines were compared (Fig. 7). Western blot analysis was also performed on the twelve NSCLC cell lines listed in Table 1 for over forty proteins that act in a variety of biological processes including stress response, drug resistance, metabolism, differentiation
and antioxidant response (data not shown). The expression level of Nrf2 protein was found to correlate well with CBP501 sensitivity in the same set of NSCLC cell lines (Fig.2B, C). Based on these analyses, focused was placed on the mRNA expression levels of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub- familyC member2 (ABCC2), Aldo-keto reductase family 1C 1 (AKR1C 1) and AKR1 C3 from Fig. 2 A because expression of these genes is known to be regulated by a common transcription factor Nrf2 (16-20). It was confirmed that the levels of protein expression correlated with mRNA expression by Western blot analysis (Fig.2D).
[0108] Immunocytochemistry was used to examine intra-cellar localization of Nrf2 in several NSCLC cell lines. These tests revealed both a high degree of nuclear localization for Nrf2 as well as a significantly higher level of whole cell expression for Nrf2 in CBP501 insensitive cell lines compared to CBP501 sensitive cell lines (Fig.3). These results indicated that high levels of expression of Nrf2 protein in CBP501 -insensitive cell lines result in high levels of target gene expression.
[0109] CBP501 sensitivity is affected by the availability of Nrf2
[0110] Western blot analyses were performed to examine the expression levels of additional known gene targets for Nrf2 (16-20). NAD(P)H dehydrogenase, quinonel (NQOl), A R1B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) and Glutathione peroxidasel (GPX1) each showed higher levels of expression in CBP501- insensitive cell lines (Fig.4A). These results support that expression of Nrf2 target genes is enhanced in CBP501 -insensitive cell lines under normal culture conditions.
[0111] In order to demonstrate a direct causal relationship between CBP501 sensitivity and Nrf2 expression, a stable Nrf2 knock-down cell line of HI 703 which is sensitive to CBP501 was produced (Fig.4B). The triple exposure of this cell line to CBP501 , CDDP and SFN, a known Nrf2 activator (17) was studied. As shown in Fig. 4B, SFN caused Nrf2 protein levels to increase in a dose dependent manner in the cells transfected with a control shRNA. SFN did not cause a similar increase the levels of Nrf2 protein in cells transfected with Nrf2 shRNA. Addition of SFN attenuated CBP501 's effect in cells transfected with control shRNA (Fig.4C, D). However, the effect of SFN was abrogated in the Nrf2 knock-down strain
(Fig.4B-D).
[0112] The effect of Nrf2 knock-down in the CBP501 insensitive cell line H1437 was investigated. Nrf2 knock-down was found to cause reduced levels of expression for
A R1C3, G6PD and GSR (Fig.5A). For this knock-down cell line, CBP501 was found to
increase the effects of CDDP on changes in the cell cycle distribution of subGl and G2-M, reversing the initial CBP501-insensitivity. On the other hand, a cell line transfected with control shRNA showed no difference in CDDP activity with or without CBP501 (Fig.5B, C). These results indicate that high Nrf2 expression levels might induce resistance to CBP501.
[0113] The high expression of Nrf2 protein is a candidate marker to predict resistance to CBP501 ; Nrf2 targets, at either the protein or mRNA level, are additional candidate markers
[0114] Although the expression of Nrf2 or its several downstream transcription targets may possibly predict resistance to CBP501, the general reliability of these predictive markers for CBP501 -sensitivity remained to be established. The combination effect of CBP501 and CDDP in sixteen additional NSCLC cell lines, classifying each as CBP501 sensitive or insensitive by the prior criteria was analyzed (Table 2). Classification of CBP501 sensitivity in additional NSCLC cell lines.
Table 2
CM B«* Oifl* OVS rn 0?C8P;<01
SSSOS By C'S?,501
CI-H 1755 1
MC1-H3SS t
WCI-H727 1
NCI-H 1563 1 .5 auw ;v*
NC1-H647 1.5
NCI-H 1155 1.5
N C I-- 520 2
A5 9 2
NC I-H 1993 2 lav*
N CI-H 1734 2
NCI-H522 2
NC I-HS3S 2
NCI-H 19T5 2 s*nsitlv*
'H C C-S27 4
MCI-H23- 4
NCI-H 1299 8
[0115] These cell lines were then subjected to the same Microarray analysis as for the initial twelve cell lines. Gene expression heat maps for the expanded set of twenty eight cell lines were again analyzed to identify prediction marker candidates for CBP501 sensitivity having more than seventy percent accuracy. Seven such genes, including three Nrf2 target genes GSR (85.7% prediction rate), AKR1C3 (75%) and G6PD (85.7%), were identified (Fig.6A). Expression levels of the corresponding proteins in these cell lines were also
confirmed by Western blotting (Fig. 6B). Notably, the high expression levels of AKR1C3 and GSR remained comparably correlated with resistance to CBP501 and Nrf2 expression (Fig.6B, C). To investigate the practical utility of this observation, several NSCLC cell lines were examined to determine whether detection of protein expression of AKR1C3 by immunocytochemical methods might serve as a possible predictive marker for CBP501 sensitivity. Such methodology promises to be a generally applicable for marker detection, since it is sufficiently sensitive to detect expressed protein levels in the small tissue samples that are typically available from NSCLC tumor biopsies (21). From these tests, it was concluded that higher levels of AKRIC3 could indeed be detected in CBP501 -insensitive cell lines compared with CBP501 -sensitive cell lines (Fig.6D, E) similar to the results with Nrf2 (Fig.3 and 6B). These results indicate that immunohistochemical detection of Nrf2 and a series of Nrf2 gene target molecules can be highly reliable markers for predicting resistance to CBP501, at least in vitro.
[0116] It has been indicated that CBP501 has at least two mechanisms of action as an anti- cancer drug candidate (8, 9). One of these, G2 checkpoint abrogation, occurs for treatments of longer duration and at higher doses (8). A second anti-cancer activity of CBP501, the enhancement of CDDP uptake through the binding to calmodulin, occurs for treatments of shorter duration and at lower doses (9). In this Example, focus is placed on the latter effect and characterized the CBP501 sensitivity of many different NSCLC cell lines by treating cells for shorter duration with lower doses of CBP501. The detailed molecular mechanism of this secondary anti-cancer activity of CBP501 remains to be elucidated because the CBP501- calmodulin interaction appears to affect several of the numerous channels and transporters implicated in CDDP uptake (10). These ambiguities about CDDP uptake complicated the identification of single CDDP transport pathway most uniquely affected by CBP501. CBP501 sensitivity was predicted by identifying major differences in gene expression profiles between CBP501 sensitive and insensitive cell lines, as determined by microarray analysis. This comprehensive analysis of gene expression initially led to several candidates for predictive markers of CBP501 sensitivity. Increased expression of genes from a common transcriptional pathway regulated by Nrf2 was identified as a possible indicator of insensitivity to CBP501. Nrf2 is known to be a key transcription factor for genes related to cytoprotective function (22-26). Under homeostatic conditions, Nrf2 is maintained at very low intracellular concentration by the proteasomal degradation system through its association with Kelch-like ECH associated protein 1 (Keapl) and the Cul3 E3 ligase (27-30). It was found that Nrf2 protein expression levels were higher in CBP501 insensitive cell lines than in
CBP501 -sensitive cell lines. However, Keapl expression levels did not correlate as well with sensitivity to CBP501 (Fig.2B). This result might indicate that the ability of Nrf2 protein to degrade under homeostatic conditions varies among different cell lines. Several reports indicated a relationship between Keapl mutation and poor prognosis or chemoresistance in NSCLC cell lines and tumours (31-33). Keapl mutations are present in a series of NSCLC cell lines that were used in this Example (Table 3 below). Keapl mutations had a tendency to be present in CBP501 -insensitive cell lines. This indicates that Keapl mutation status is a useful indicator of resistance to CBP501. The role of each mutation type will be further verified.
[0117]
Table 3
[0118] Differential expression of several Nrf2 target genes at the RNA or protein level was identified as a means to identify candidates for markers to predict CBP501 insensitivity. Of these initial candidates, G6PD, GSR and AKR1C3 showed significant differences in both mRNA and protein expression levels between CBP501 sensitive and insensitive cell lines. Regulation of the expression of these identified genes was recognized as being under the common control of Nrf2 binding elements called AREs (antioxidant response elements) (23). Several known transcription factors can antagonize Nrf2 by competing for interaction at
AREs. These include the small MAF proteins, BACHl , c-FOS and FRAl (23, 34, 35). These transcriptional regulators might be involved in controlling the differential expression of different Nrf2 target genes. In fact, BACHl protein is one for which expression in NSCLC cell lines appears to increase in CBP501 sensitive cell lines (Fig.2B).
[0119] Nrf2 participates in a diverse spectrum of different biological phenomena, including metabolism, the xenobiotic response, and the antioxidant response, by inducing the expression of numerous genes (22-26). For instance, inducing the expression of G6PD and GSR elevates glutathione levels and this leads to the antioxidant response (36, 37). AKR1C3 can mediate pathways leading to the synthesis of testosterone and to prostaglandin formation (38, 39). Although Nrf2 knock-down experiments indicate that Nrf2 might modulate the CBP501 sensitivity, there is still no definitive answer about which Nrf2 target gene or phenomena directly affect CBP501 -sensitivity. One or several Nrf2 target genes might be involved in determining cell sensitivity to CBP501 's effects on CDDP uptake. Such direct
effects might be difficult to detect by conventional microarray analysis which can sometimes be hindered by technical limitations such as variable sensitivity in the detection of individual probes. Although it has been indicated that the CBP501/CDDP combination effect on short term exposure correlated well with CDDP uptake in at least seven cell lines (9), platinum accumulation in NSCLC cell lines was not demonstrated. So there was a possibility that CBP501 affected not only enhancement of CDDP uptake but also inhibition of the Nrf2 dependent cytoprotective effect against CDDP. For example, reduced glutathione (GSH), which can be up-regulated by Nrf2, binds to CDDP and can decrease toxicity (40). However, measured levels of intracellular reduced GSH in NSCLC cell lines do not correlate with CBP501 sensitivity (data not shown). Clearly, further investigation is needed to establish a concrete mechanism by which Nrf2 regulates CBP501 insensitivity.
[0120] For the actual selection of patients who might be benefited by CBP501 sensitivity, though, immunohistochemistry (IHC) may be a first-line method of choice since it may be possible to obtain a clear indication of sensitivity from the small tumor samples that are available through biopsy. Smaller samples can be analyzed by IHC than by Western blotting (21). Investigations into immunocytochemical measurements for Nrf2, A R1C 1, AKR1 B 10 and AKR1C3 indicated that they reliably reproduced the results obtained in Western blotting experiments (Fig.3, 6C, D, Figs. 8 and 9). Validation of the use of IHC to detect these proteins in tumor biopsy samples and further validation of the correlation with CBP501 - sensitivity can provide a useful tool to predict a patient's increased responsiveness to combined CDDP + CBP501 therapy.
References
I . Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013;6:563-76
2. oudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer - genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157: 125-36
3. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17: 1351-75
4. Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the
management of metastatic melanoma. Pharmgenomics Pers Med 2012;5: 139-48
5. Shapiro GI. Tibes R, Gordon MS. Wong BY. Eder JP. Borad MJ. et al. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 201 1 ; 17:3431 -42
6. Lee MK, Antoinette JW, Hedy L , Ronald F, Marianna , Jose LM, et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). ASCO annual meeting 2012;No.7029
7. Matsumoto Y. Shindo Y. Takakusagi Y. Takakusagi K. Tsukuda S. Kusayanagi T, et al.
Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501 -binding site. Bioorg Med Chem 201 1 ;19:7049-56
8. Sha SK. Sato T. Kobayashi H. Ishigaki M. Yamamoto S. Sato H. et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 check point. Mol Cancer Ther 2007;6: 147-53
9. Mine N. Yamamoto S. Saito N. Yamazaki S. Suda C. Ishigaki M. et al. CBP501- calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol Cancer Ther 201 1 ; 10: 1929-38
10. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 201 1 ; 14:22-34
I I . Hirotsu Y. Katsuoka F, Funayama R, Nagashima T. Nishida Y. Nakayama K. et al. Nrf2- MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res 2012;40: 10228-39
12. DeNicola GM. Karreth FA. Humpton TJ. Gopinathan A. Wei C. Frese K. et al.
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 201 1 ;475: 106-9
13. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap l-Nrf2 pathway in stress response and cancer evolution. Genes to Cells 201 1 ;16: 123-40
14. Kawabe T. G2 checkpoint abrogators as anti-cancer drugs. Mol Cancer Ther 2004;3:513- 9
15. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001 ;61 :4301-5
16. Mahaffey CM, Zhang H. Rinna A, Holland W. Mack PC. Forman HJ. Multidrug- resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med 2009;46: 1650-7
17. MacLeod AK. McMahon M. Plummer SM. Higgins LG. Penning TM. Igarashi K. et al.
Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009;30: 1571-80
18. Aleksunes LM. Goedken MJ. Rockwell CE, Thomale J. Manautou JE. Klaassen CD.
Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 2010;335:2-12
19. Abdullah A. Kitteringham NR. Jenkins RE. Goldring C. Higgins L. Yamamoto M. et al.
Analysis of the role of Nrf2 in the expression of liver proteins in mice using two- dimensional gel-based proteomics. Pharmacol Rep 2012;64:680-97
20. Wu KC, Cui JY, Klaassen CD. Effect of graded NrO activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. PLoS One 2012;7:e39006
21. Besse B, Olaussen KA, Soria JC. ERCC 1 and RRM1 : ready for prime time? J Clin Oncol 2013;31 : 1050-60
22. Wakabavashi N. Slocum SL. Skoko JJ. Shin S. Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal 2010; 13: 1649-63
23. Hu R. Saw CL. Yu R. Kong AN. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal 2010; 13: 1679-98
24. Brigelius-Flohe R, Miiller M, Lippmann D, Kipp AP. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int J Cell Biol 2012;2012:486147
25. Ashrafian H, Czibik G, Bellahcene M, Aksentijevic D, Smith AC, Mitchell SJ, et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 2012; 15:361 -71
26. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.
Cancer Cell 2012;22:66-79
27. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keapl represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86
28. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keapl -BTB protein is an
adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3- Keapl ligase. Mol Cell Biol 2004;24:8477-86
29. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keapl functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24:7130-9
30. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap l is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24: 10941 -53
31. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420
32. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, et al. A catalog of genes homozyugously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010;49:342-52
33. Sporn MB and Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;8:564-71
34. Venugopal R, Jaiswal AK. Nrfl and Nrf2 positively and c-Fos and Fral negatively
regulate the human antioxidant response element-mediated expression of
NAD(P)H:quinone oxidoreductasel gene. Proc Natl Acad Sci 1996;93: 14960-5
35. Nguyen T, Huang HC, Pickett CB. Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem 2000;275: 15466-73
36. Mulquiney PJ, Kuchel PW. Model of 2,3-bisphosphoglycerate metabolism in the human erythrocyte based on detailed enzyme kinetic equations: equations and parameter refinement. Biochem J 1999;342:581 -96
37. Coelho PM, Salvador A, Savageau MA. Relating mutant genotype to phenotype via
quantitative behavior of the NADPH redox cycle in human erythrocytes. PLoS One 2010;5:el3031
38. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:553-624
39. Byrns MC, Jin Y, Penning TM. Inhibitors of type 5 17p-hydroxysteroid dehydrogenase (A R1 C3): overview and structural insights. J Steroid Biochem Mol Biol 201 1 ; 125:95- 104
40. Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010;430939: 1-7
Claims
1. A method for treating a cancer in a subject, comprising,
a. ) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer;
b. ) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene; and
c. ) treating the subject having the cancer with CBP501 if expression of the NRF2, or the NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene.
2. A method for treating a cancer in a subject, comprising,
a. ) screening for a normal or a functional KEAP 1, or a mutation that reduces or decreases activity, function or expression of KEAP 1, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the presence of a normal or a functional KEAP 1 , or a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and
b. ) treating the subject having the cancer with CBP501 if the subject expresses a normal or a functional KEAP 1, or the subject does not have a mutation that reduces or decreases activity, function or expression of KEAP 1.
3. A method for treating a cancer in a subject with CBP501, comprising,
a. ) identifying and/or selecting a subject with a cancer: (i) in which NRF2 expression or NRF2 target gene expression in the subject is less than a baseline or reference amount of NRF2 or NRF2 target gene, or (ii) has normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and
b. ) treating the cancer in the subject with CBP501 : (i) if the NRF2 or the NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene, or (ii) if the subject has normal or a functional KEAP 1 or the
subject does not have a mutation that reduces or decreases activity, function or expression of KEAP 1.
4. A method for selecting a subject for cancer treatment with CBP501, comprising, a.) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample;
b. ) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene, thereby determining if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene; and
c. ) selecting the subject for cancer treatment with CBP501 if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
5. A method for selecting a subject for cancer treatment with CBP501, comprising, a.) measuring screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and
b.) selecting the subject for cancer treatment with CBP501 if the subject has a normal or a functional KEAP 1, or the subject lacks a mutation that reduces or decreases activity, function or expression of KEAP 1.
6. A method for identifying a candidate subject for cancer treatment with CBP501 , comprising,
a.) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or NRF2 target gene in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 or NRF2 target gene in the subject or cancer sample;
b.) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 in order to determine if the amount of NRF2 or NRF2 target gene is less than the baseline or reference amount of NRF2 or NRF2 target gene; and
c.) identifying the subject as a candidate for cancer treatment with CBP501 if the NRF2 or NRF2 target gene in the sample or in the subject is less than the baseline or reference amount of NRF2 or NRF2 target gene.
7. A method for identifying a candidate subject for cancer treatment with CBP501 , comprising,
a. ) screening for a mutation that reduces or decreases activity, function or expression of KEAP 1 ; and
b. ) identifying the subject as a candidate for cancer treatment with CBP501 if the subject has a normal or a functional KEAP 1, or if the subject lacks a mutation that reduces or decreases activity, function or expression of KEAP 1.
8. A method for characterizing a cancer as more responsive or less responsive to treatment with CBP501, comprising,
a.) measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2) or
NRF2 target gene of cells of a cancer, and determining the amount of NRF2 or NRF2 target gene expressed;
b. ) comparing the amount of NRF2 determined, or NRF2 target gene determined, to a predetermined value for NRF2 or NRF2 target gene in order to determine if the amount of NRF2 or NRF2 target gene is less or greater than the predetermined value for NRF2 or NRF2 target gene; and
c. ) characterizing the cancer as more responsive or less responsive to treatment with CBP501 if the NRF2 or NRF2 target gene expression is less than or greater than the predetermined value for NRF2 or NRF2 target gene.
9. A method for characterizing a cancer as more responsive to treatment with CBP501, comprising,
a.) screening for a normal or a functional KEAP 1 or a mutation that reduces or decreases activity, function or expression of KEAP 1 ;
b.) characterizing the cancer as more responsive to treatment with CBP501 if a normal or a functional KEAP 1 is present, or a mutation that reduces or decreases activity, function or expression of KEAP 1 is absent or not present.
10. The method of any of claims 1, 3, 4, 6 or 8, wherein the NRF2 target gene is any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase familylC l (AKRIC I ), Aldo- keto reductase familylC3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX 1).
1 1. The method of any of claims 1, 3, 4, 6 or 8, wherein the baseline or reference level or predetermined value is determined by expression in cancer cells responsive to CBP501 treatment compared to cancer cells less-responsive to CBP501 treatment.
12. The method of any of claims 1 -9, wherein the sample comprises a biological sample.
13. The method of any of claims 1 -9, wherein the sample comprises a cell, tissue or organ biopsy, or a blood or serum sample.
14. The method of any of claims 1-9, wherein the sample comprises a lung biopsy.
15. The method of any of claims 1 -9, wherein the subject is a mammal.
16. The method of any of claims 1 -9, wherein the subject is a human.
17. The method of any of claims 1 -9, wherein expression is measured by a quantitative assay.
18. The method of any of claims 1-9, wherein expression is measured or detection is by contact with an analyte that detects the NRF2 protein, or the protein encoded by the NRF2 target gene, or detects the mutation that reduces or decreases activity, function or expression of KEAP 1.
19. The method of any of claims 1-9, wherein expression is measured or detection by contact with an analyte that detects the NRF2 transcript, or the transcript of the NRF2 target
gene, or by sequencing a nucleic acid that comprises the mutation that reduces or decreases activity, function or expression of KEAP 1.
20. The method of any of claims 1-9, wherein expression is measured or detection is by an immunoassay.
21. The method of any of claims 1-9, wherein expression is measured or detection is by an antibody immunoassay.
22. The method of any of claims 1-9, wherein expression is measured or detection is by a Western blot, ELISA, Northern blot, immunohistochemistry or immunocyotchemistry.
23. The method of any of claims 1-9, wherein expression is measured or detection is by determining cDNA of NRF2 or cDNA of NRF2 target gene.
24. The method of any of claims 1 -9, wherein expression is measured or detection is by reverse transcription of NRF2 RNA or NRF2 target gene RNA and polymerase chain reaction (RT-PCR) of NRF2 cDNA or NRF2 target gene cDNA, or reverse transcription of KEAP 1 RNA or KEAP 1 gene and polymerase chain reaction (RT-PCR) of KEAP 1 cDNA.
25. The method of any of claims 1-9, wherein the CBP501 comprises a salt of pro-drug thereof.
26. The method of any of claims 1 -9, wherein the CBP501 salt comprises a sodium, calcium, magnesium, nitrate, potassium, phosphate, sulfonate, fumarate, citrate, carbonate, ascorbate, succinate, trifluoroacetate or acetate salt.
27. The method of any of claims 1-9, further comprising administering a G2 checkpoint inhibitor agent.
28. The method of any of claims 1-9, further comprising administering a calmodulin binding agent.
29. The method of any of claims 1 -9, further comprising administering a nucleic acid damaging agent to the subject.
30. The method of any of claims 1-9, wherein the nucleic acid damaging agent comprises a molecule that binds to or intercalates in DNA.
31. The method of any of claims 1-9, comprising administering CBP501, a G2 checkpoint inhibitor agent, a calmodulin binding agent or a nucleic acid damaging agent to the subject 1 , 2, 3, 4, 5, or more times, alone, or in any combination.
32. The method of any of claims 1-9, wherein the cancer comprises a lung cancer (NSCLC).
33. A population of cancer cells, wherein the cells are fixed or immobilized on a substrate and wherein the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or EAP 1 protein.
34. A population of cancer cells obtained from a subject, wherein the cells are fixed or immobilized on a substrate and wherein the cells have bound thereto a reagent that detects NRF2 protein, or a protein encoded by an NRF2 target gene, or KEAP 1 protein.
35. The population of cells of any of claims 33-34, wherein the reagent that detects NRJF2 protein or protein encoded by an NRF2 target gene or KEAP 1 protein comprises an antibody.
36. A population of cancer cells, wherein the cells are fixed or immobilized on a substrate and wherein the cells have bound thereto a reagent that selectively binds to NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript.
37. A population of cancer cells obtained from a subject, wherein the cells are fixed or immobilized on a substrate and wherein the cells have bound thereto a reagent that selectively binds to an NRF2 transcript, or a transcript of an NRF2 target gene, or KEAP 1 transcript.
38. The population of cells of any of claims 36-37, wherein the reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene comprises an oligonucleotide or primer.
39. The population of cells of any of claims 33-38, wherein the NRF2 target gene is any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP-binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase familylC l (AKR1C 1), Aldo- keto reductase familyl C3 (A R1C3), NAD(P)H dehydrogenase, quinonel ( QOl), A R1B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidase 1 (GPX 1).
40. A composition comprising nucleic acid isolated, purified or extracted from a population of cancer cells, wherein the nucleic acid comprises NRF2 gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or a transcript thereof, or binds to EAP 1 gene or a transcript thereof.
41. A composition comprising nucleic acid isolated, purified or extracted from a population of cancer cells, wherein the nucleic acid comprises an NRF2 target gene or transcript thereof bound to a reagent that selectively binds to NRF2 gene or transcript thereof, or binds to KEAP 1 gene or a transcript thereof.
42. The composition of any of claims 40-41 , wherein the reagent that selectively binds to NRF2 transcript, or transcript of an NRF2 target gene comprises an oligonucleotide or primer.
43. A composition comprising protein isolated, purified or extracted from a population of cancer cells, wherein the protein comprises NRF2 protein bound to a reagent that selectively detects NRF2 protein, or KEAP 1 protein bound to a reagent that selectively detects KEAP 1 protein.
44. A composition comprising protein isolated, purified or extracted from a population of cancer cells, wherein the protein comprises a protein encoded by an NRF2 target gene bound to a reagent that selectively detects the protein encoded by an NRF2 target gene.
45. The composition of any of claims 43-44, wherein the reagent that selectively detects NRF2 protein, or protein encoded by an NRF2 target gene, or KEAP 1 protein comprises an antibody.
46. The composition of any of claims 40-45, wherein the NRF2 target gene is any of Glutathione reductase (GSR), Glucose-6-phosphate dehydrogenase (G6PD), ATP -binding cassette sub-familyC member2 (ABCC2), Aldo-keto reductase familylC l (AKRIC I), Aldo- keto reductase familyl C3 (AKR1C3), NAD(P)H dehydrogenase, quinonel (NQOl), AKR1B 10, γ-glutamyl cysteine synthetase modifier subunit (yGCSm) or Glutathione peroxidasel (GPX1).
47. The population of cells of any of claims 33-37, wherein the substrate comprises a glass or plastic plate, slide or chip.
48. The composition of any of claims 40-46, wherein the composition comprises a solution.
49. The population of cells of any of claims 33-39 or 47, or the composition of any of claims 40-46 or 48, wherein cancer cells comprise lung cancer (NSCLC).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016562613A JP2017519185A (en) | 2014-05-22 | 2015-05-21 | NRF2-based cancer treatment and detection methods and uses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462002076P | 2014-05-22 | 2014-05-22 | |
US62/002,076 | 2014-05-22 | ||
US201462036476P | 2014-08-12 | 2014-08-12 | |
US62/036,476 | 2014-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015178508A1 true WO2015178508A1 (en) | 2015-11-26 |
Family
ID=54554164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/065702 WO2015178508A1 (en) | 2014-05-22 | 2015-05-21 | Nrf2-based cancer treatment and detection methods and uses |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160061841A1 (en) |
JP (1) | JP2017519185A (en) |
TW (1) | TW201622739A (en) |
WO (1) | WO2015178508A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009939A1 (en) * | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene. |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210085763A1 (en) * | 2019-09-23 | 2021-03-25 | New York University | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007521256A (en) * | 2003-06-25 | 2007-08-02 | 株式会社 キャンバス | Peptides and peptidomimetics having immunomodulatory activity, anti-inflammatory activity, and antiviral activity |
JP2009171920A (en) * | 2008-01-28 | 2009-08-06 | Bio Regenerations:Kk | Method for screening anticancer agent |
WO2011083637A1 (en) * | 2010-01-07 | 2011-07-14 | 財団法人東京都医学総合研究所 | Therapeutic agent for hepatic disorder |
JP2011528894A (en) * | 2008-07-25 | 2011-12-01 | インフォコム株式会社 | New oncogene NRF2 |
-
2015
- 2015-05-21 WO PCT/JP2015/065702 patent/WO2015178508A1/en active Application Filing
- 2015-05-21 JP JP2016562613A patent/JP2017519185A/en active Pending
- 2015-05-21 US US14/719,088 patent/US20160061841A1/en not_active Abandoned
- 2015-05-22 TW TW104116609A patent/TW201622739A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007521256A (en) * | 2003-06-25 | 2007-08-02 | 株式会社 キャンバス | Peptides and peptidomimetics having immunomodulatory activity, anti-inflammatory activity, and antiviral activity |
JP2009171920A (en) * | 2008-01-28 | 2009-08-06 | Bio Regenerations:Kk | Method for screening anticancer agent |
JP2011528894A (en) * | 2008-07-25 | 2011-12-01 | インフォコム株式会社 | New oncogene NRF2 |
WO2011083637A1 (en) * | 2010-01-07 | 2011-07-14 | 財団法人東京都医学総合研究所 | Therapeutic agent for hepatic disorder |
Non-Patent Citations (6)
Title |
---|
GEOFFREY I. SHAPIRO ET AL.: "Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors", CLINICAL CANCER RESERCH, vol. 17, no. 10, 10 January 2011 (2011-01-10), pages 3431 - 3442, XP055238063, ISSN: 1078-0432 * |
JONG-MIN LEE ET AL.: "Identification of the NF-E2-related Factor-2-dependent Genes Conferring Protection against Oxidative Stress in Primary Cortical Astrocytes Using Oligonucleotide Microarray Analysis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 14, 28 January 2003 (2003-01-28), pages 12029 - 12038, XP055238056, ISSN: 0021-9258 * |
MASASHI SUGANUMA ET AL.: "Sensitization of Cancer Cells to DNA Damage-induced Cell Death by Specific Cell Cycle G2 Checkpoint Abrogation", CANCER RESEARCH, vol. 59, 1 December 1999 (1999-12-01), pages 5887 - 5891, XP002181465, ISSN: 0008-5472 * |
MI-KYOUNG KWAK ET AL.: "Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keapl-Nrf2 Pathway", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 10, 27 December 2002 (2002-12-27), pages 8135 - 8145, XP002486450, ISSN: 0021-9258 * |
NAOKI MINE ET AL.: "Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 9, 22 July 2014 (2014-07-22), pages 2215 - 2225, XP055238059, ISSN: 1535-7163 * |
SHI-KEN SHA ET AL.: "Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint", MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 1, January 2007 (2007-01-01), pages 147 - 153, XP055238054, ISSN: 1535-7163 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009939A1 (en) * | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene. |
CN109890982A (en) * | 2016-07-08 | 2019-06-14 | 基因泰克公司 | Pass through the method for the expression status and mutation status diagnosing and treating cancer of NRF2 and its downstream targets gene |
JP2019531699A (en) * | 2016-07-08 | 2019-11-07 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment method of cancer by expression state and mutation state of NRF2 and downstream target gene of the gene |
US11066709B2 (en) | 2016-07-08 | 2021-07-20 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene |
JP7050702B2 (en) | 2016-07-08 | 2022-04-08 | ジェネンテック, インコーポレイテッド | Methods for diagnosing and treating cancer based on the expression status and mutation status of NRF2 and its downstream target gene |
CN109890982B (en) * | 2016-07-08 | 2023-07-07 | 基因泰克公司 | Method for diagnosing and treating cancer by expression status and mutation status of NRF2 and target genes downstream thereof |
Also Published As
Publication number | Publication date |
---|---|
US20160061841A1 (en) | 2016-03-03 |
JP2017519185A (en) | 2017-07-13 |
TW201622739A (en) | 2016-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7834163B2 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy | |
Hoffmann et al. | Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma | |
Hansen et al. | The importance of− 460 C/T and+ 405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer | |
US20080254031A1 (en) | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis | |
CA2772643C (en) | Methods and compositions for detection of lethal cell and uses thereof | |
Hoshino et al. | Molecular localization and characterization of multiple binding sites of organic anion transporting polypeptide 2B1 (OATP2B1) as the mechanism for substrate and modulator dependent drug–drug interaction | |
US20120141376A1 (en) | Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics | |
KR20130091746A (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
JP2018148886A (en) | Biomarkers associated with CDK inhibitors | |
US20160061841A1 (en) | Nrf2-based cancer treatment and detection methods and uses | |
CA2840129A1 (en) | Method for predicting the clinical response to chemotherapy in a subject with cancer | |
EP2628011B1 (en) | Ilk gene as marker for erlotinib treatment | |
EP2606358B1 (en) | Bard1 isoforms in lung and colorectal cancer and use thereof | |
JP2007215412A (en) | Method for judging malignant metastatic stomach cancer | |
WO2014176047A1 (en) | Markers for ezh2 inhibitors | |
EP1673630A2 (en) | Mn/ca ix and cancer prognosis | |
US20200003779A1 (en) | Method and device for detecting siglec12 | |
US20160327558A1 (en) | Means and methods for detecting activated malt1 | |
US9903871B2 (en) | Stabilized peptide fragments from nucleoredoxin X1 and uses thereof | |
US7645589B2 (en) | Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma | |
WO2014062635A1 (en) | Markers for acute lymphoblastic leukemia | |
US9267119B2 (en) | Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers | |
WO2012075318A2 (en) | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer | |
WO2023220648A2 (en) | Compositions and methods for detecting and treating tumors and/or cancers associated with braf and/or map2k1 variants | |
CN114214418A (en) | Biomarker for evaluating sensitivity of lung cancer patient to proton radiotherapy and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15795584 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016562613 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15795584 Country of ref document: EP Kind code of ref document: A1 |